


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:56Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406369" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406369</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>liphdis</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Lipids Health Dis</journal-id><journal-id journal-id-type="iso-abbrev">Lipids Health Dis</journal-id><journal-id journal-id-type="pmc-domain-id">116</journal-id><journal-id journal-id-type="pmc-domain">liphdis</journal-id><journal-title-group><journal-title>Lipids in Health and Disease</journal-title></journal-title-group><issn pub-type="epub">1476-511X</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406369</article-id><article-id pub-id-type="pmcid-ver">PMC12406369.1</article-id><article-id pub-id-type="pmcaid">12406369</article-id><article-id pub-id-type="pmcaiid">12406369</article-id><article-id pub-id-type="pmid">40898170</article-id><article-id pub-id-type="doi">10.1186/s12944-025-02657-9</article-id><article-id pub-id-type="publisher-id">2657</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>From guidelines to practice: LDL-C achievement in very high cardiovascular risk patients &#8211; analysis of the EDHIPO MARCA registry</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2401-6413</contrib-id><name name-style="western"><surname>Cordoba-Melo</surname><given-names initials="BD">Brayan Daniel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0006-2151-0722</contrib-id><name name-style="western"><surname>Seni-Molina</surname><given-names initials="S">Sebasti&#225;n</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3601-3279</contrib-id><name name-style="western"><surname>Arango-Ibanez</surname><given-names initials="JP">Juan Pablo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3458-4246</contrib-id><name name-style="western"><surname>Ayala</surname><given-names initials="MR">Milton Ren&#233;</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0009-3097-2234</contrib-id><name name-style="western"><surname>Tatis-M&#233;ndez</surname><given-names initials="JF">Jos&#233; Fidel</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8193-6369</contrib-id><name name-style="western"><surname>Quintero Yepez</surname><given-names initials="V">Viviana</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8201-0322</contrib-id><name name-style="western"><surname>Mej&#237;a Cadavid</surname><given-names initials="LA">Luz A&#237;da</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4593-6155</contrib-id><name name-style="western"><surname>Cruz-Cuevas</surname><given-names initials="JD">Jos&#233; D.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4137-8774</contrib-id><name name-style="western"><surname>Ariza-Ord&#243;&#241;ez</surname><given-names initials="N">Nicol&#225;s</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7693-0771</contrib-id><name name-style="western"><surname>Buitrago</surname><given-names initials="A">Andr&#233;s</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8865-0929</contrib-id><name name-style="western"><surname>Lopez-Lopez</surname><given-names initials="JP">Jose Patricio</given-names></name><xref ref-type="aff" rid="Aff11">11</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hinestrosa</surname><given-names initials="A">Alfredo</given-names></name><xref ref-type="aff" rid="Aff12">12</xref><xref ref-type="aff" rid="Aff13">13</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sabogal</surname><given-names initials="J">Jorge</given-names></name><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reyes-Vargas</surname><given-names initials="C">Cristian</given-names></name><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6891-1837</contrib-id><name name-style="western"><surname>Herrera-Escandon</surname><given-names initials="&#xC1;">&#193;lvaro</given-names></name><xref ref-type="aff" rid="Aff16">16</xref><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hurtado</surname><given-names initials="JS">Juan Sebasti&#225;n</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0003-7510-2132</contrib-id><name name-style="western"><surname>Vel&#225;squez Osorio</surname><given-names initials="JF">Juan Fernando</given-names></name><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Londo&#241;o</surname><given-names initials="S">Sergio</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Salamanca</surname><given-names initials="C">Carlos</given-names></name><xref ref-type="aff" rid="Aff20">20</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5946-2408</contrib-id><name name-style="western"><surname>Vallecilla</surname><given-names initials="L">Liliana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8854-105X</contrib-id><name name-style="western"><surname>Leon-Giraldo</surname><given-names initials="H">Hoover</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6528-4268</contrib-id><name name-style="western"><surname>Ruiz</surname><given-names initials="AJ">Alvaro J.</given-names></name><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8006-915X</contrib-id><name name-style="western"><surname>Molina</surname><given-names initials="DI">Dora In&#233;s</given-names></name><xref ref-type="aff" rid="Aff22">22</xref><xref ref-type="aff" rid="Aff23">23</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6635-6224</contrib-id><name name-style="western"><surname>Gomez-Mesa</surname><given-names initials="JE">Juan Esteban</given-names></name><address><email>juan.gomez.me@fvl.org.co</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff24">24</xref></contrib><contrib contrib-type="author"><collab>On Behalf of EDHIPO MARCA Research Group</collab></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00xdnjz02</institution-id><institution-id institution-id-type="GRID">grid.477264.4</institution-id><institution>Centro de Investigaciones Cl&#237;nicas, </institution><institution>Fundaci&#243;n Valle del Lili, </institution></institution-wrap>Cali, Colombia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02t54e151</institution-id><institution-id institution-id-type="GRID">grid.440787.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9702 069X</institution-id><institution>Facultad de Ciencias de la Salud, </institution><institution>Universidad Icesi, </institution></institution-wrap>Cali, Colombia </aff><aff id="Aff3"><label>3</label>Departamento de Cardiolog&#237;a, Cl&#237;nica Las Am&#233;ricas AUNA, Medell&#237;n, Colombia </aff><aff id="Aff4"><label>4</label>Investigaci&#243;n Aplicada y Epidemiol&#243;gica, Fundaci&#243;n Ideas AUNA, Medell&#237;n, Colombia </aff><aff id="Aff5"><label>5</label>Servicio de Cardiolog&#237;a, Cl&#237;nica El Rosario, Medell&#237;n, Colombia </aff><aff id="Aff6"><label>6</label>Centro de Innovaci&#243;n e Investigaci&#243;n en Salud CINCRO, Cl&#237;nica El Rosario, Medell&#237;n, Colombia </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04vs72b15</institution-id><institution-id institution-id-type="GRID">grid.488756.0</institution-id><institution>Centro de investigaciones, </institution><institution>Fundaci&#243;n Cardioinfantil-Instituto de Cardiolog&#237;a, </institution></institution-wrap>Bogot&#225;, Colombia </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04vs72b15</institution-id><institution-id institution-id-type="GRID">grid.488756.0</institution-id><institution>Departamento de Cl&#237;nicas M&#233;dicas - Medicina Interna, </institution><institution>Fundaci&#243;n Cardioinfantil- Instituto de Cardiolog&#237;a, </institution></institution-wrap>Bogot&#225;, Colombia </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0108mwc04</institution-id><institution-id institution-id-type="GRID">grid.412191.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2205 5940</institution-id><institution>Escuela de Medicina y Ciencias de la Salud, </institution><institution>Universidad del Rosario, </institution></institution-wrap>Bogot&#225;, Colombia </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03ezapm74</institution-id><institution-id institution-id-type="GRID">grid.418089.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0620 2607</institution-id><institution>Departamento de Cardiolog&#237;a, </institution><institution>Fundaci&#243;n Santa Fe de Bogot&#225;, </institution></institution-wrap>Bogot&#225;, Colombia </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04n6qsf08</institution-id><institution-id institution-id-type="GRID">grid.442204.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0486 1035</institution-id><institution>Instituto de Investigaciones MASIRA, </institution><institution>Universidad de Santander, </institution></institution-wrap>Bucaramanga, Colombia </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05xvh6h11</institution-id><institution-id institution-id-type="GRID">grid.488459.c</institution-id><institution>Unidad de Cuidados Intensivos, Los Comuneros &#8211; Hospital Universitario de Bucaramanga, </institution></institution-wrap>Bucaramanga, Colombia </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05xvh6h11</institution-id><institution-id institution-id-type="GRID">grid.488459.c</institution-id><institution>Direcci&#243;n M&#233;dica, </institution><institution>Los Comuneros &#8211; Hospital Universitario de Bucaramanga, </institution></institution-wrap>Bucaramanga, Colombia </aff><aff id="Aff14"><label>14</label>Centro de Investigaciones Cl&#237;nicas, Angiograf&#237;a de Occidente, Cali, Colombia </aff><aff id="Aff15"><label>15</label>Departamento de Cardiolog&#237;a, Cl&#237;nica Portoazul Auna, Barranquilla, Colombia </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/000p4dw82</institution-id><institution-id institution-id-type="GRID">grid.411286.8</institution-id><institution>Departamento de Cardiolog&#237;a, </institution><institution>Hospital Universitario del Valle, </institution></institution-wrap>Cali, Colombia </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00jb9vg53</institution-id><institution-id institution-id-type="GRID">grid.8271.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2295 7397</institution-id><institution>Facultad de Ciencias de la Salud, </institution><institution>Universidad del Valle, </institution></institution-wrap>Cali, Colombia </aff><aff id="Aff18"><label>18</label>Departamento de Cardiolog&#237;a, DIME Cl&#237;nica Neurocardiovascular, Cali, Colombia </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01vtn3k88</institution-id><institution-id institution-id-type="GRID">grid.413124.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 1784 5448</institution-id><institution>Departamento de Medicina Interna, </institution><institution>Hospital Pablo Tob&#243;n Uribe, </institution></institution-wrap>Medell&#237;n, Colombia </aff><aff id="Aff20"><label>20</label>Sanofi, Bogot&#225;, Colombia </aff><aff id="Aff21"><label>21</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03etyjw28</institution-id><institution-id institution-id-type="GRID">grid.41312.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 1033 6040</institution-id><institution>Departamento de Epidemiolog&#237;a Cl&#237;nica y Bioestad&#237;stica, </institution><institution>Pontificia Universidad Javeriana, </institution></institution-wrap>Bogot&#225;, Colombia </aff><aff id="Aff22"><label>22</label>Direcci&#243;n M&#233;dica, IPS M&#233;dicos Internistas de Caldas, Manizales, Colombia </aff><aff id="Aff23"><label>23</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/049n68p64</institution-id><institution-id institution-id-type="GRID">grid.7779.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2290 6370</institution-id><institution>Facultad de Ciencias de la Salud, </institution><institution>Universidad de Caldas, </institution></institution-wrap>Manizales, Colombia </aff><aff id="Aff24"><label>24</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00xdnjz02</institution-id><institution-id institution-id-type="GRID">grid.477264.4</institution-id><institution>Servicio de Cardiolog&#237;a, </institution><institution>Fundaci&#243;n Valle del Lili, </institution></institution-wrap>Carrera 98 No. 18-49, Cali, Colombia </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>24</volume><issue-id pub-id-type="pmc-issue-id">478310</issue-id><elocation-id>275</elocation-id><history><date date-type="received"><day>15</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12944_2025_Article_2657.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, with dyslipidemia playing a key role in its progression. Despite advances in lipid-lowering therapy (LLT), LDL-C (Low-Density Lipoprotein Cholesterol) goal achievement remains suboptimal. This study evaluated LDL-C goal attainment in Colombian patients with very high cardiovascular risk (CVR) due to coronary artery disease (CAD) following ESC/EAS guidelines updates.</p></sec><sec><title>Methods</title><p id="Par2">EDHIPO MARCA (<bold>E</bold>valuaci&#243;n <bold>D</bold>e adherencia a la terapia <bold>HIPO</bold>lipemiante en pacientes de <bold>M</bold>uy <bold>A</bold>lto <bold>R</bold>iesgo <bold>CA</bold>rdiovascular) is a retrospective, multicenter study assessing LDL-C goal achievement in patients with CAD. Data were collected from previous coronary angiogram reports and medical records across 11 Colombian healthcare institutions with certified interventional cardiology services. Patients with CAD who had at least one follow-up LDL-C measurement and an LLT prescription within 12 months post-angiogram were included. LDL-C goal attainment was assessed across three periods&#8212;2011&#8211;2012, 2016&#8211;2017, and 2021&#8211;2022&#8212;corresponding to the updates of ESC/EAS guidelines (2011, 2016, and 2019, respectively). The LDL-C goals were &lt;70&#160;mg/dL for the first two periods and &lt;55&#160;mg/dL for the most recent one. LDL-C was measured or estimated using the Friedewald equation. Descriptive analyses were performed.</p></sec><sec><title>Results</title><p id="Par3">A total of 1,788 patients were included, with a median age of 66 years (IQR: 59&#8211;74), and 70.7% were male. Hypertension (67.5%) and overweight (40.8%) were the most common comorbidities. At discharge, statins were prescribed in 84.1% (95% CI: 82.4&#8211;85.8%) of patients, increasing to 99.1% (95% CI: 98.6&#8211;99.5%) at the end of follow-up (median 6.8 months); PCSK9 inhibitors were prescribed in 1.5%, exclusively in 2019. At the end of follow-up, 36.6% (95% CI: 34.3%, 38.8%) achieved LDL-C goals. By guideline period, goal attainment was 12.1% (95% CI: 5.4%, 18.8%) in 2011, 42.3% (95% CI: 37.9%, 46.8%) in 2016, and 36.2% (95% CI: 33.5%, 38.9%) in 2019. By number of follow-ups, LDL-C goal achievement increased from 32.9% (1 follow-up) to 44.0% (4 follow-ups).</p></sec><sec><title>Conclusions</title><p id="Par4">Despite widespread LLT use, LDL-C target achievement remains suboptimal. Frequent follow-up and greater use of combination therapy beyond statins may be essential to improve lipid control in very high CVR patients.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12944-025-02657-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>LDL-C goal</kwd><kwd>Very high cardiovascular risk</kwd><kwd>Lipid-lowering therapy</kwd><kwd>ESC/EAS guidelines</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, posing a major global health challenge [<xref ref-type="bibr" rid="CR1">1</xref>]. Between 1990 and 2019, the number of CVD cases nearly doubled, rising from 272&#160;million to 523&#160;million, alongside an increase in deaths from 12.1&#160;million to 18.6&#160;million during the same period [<xref ref-type="bibr" rid="CR2">2</xref>]. In 2013, in the United States (US) one person died from CVD every 40&#160;s, while in Europe, atherosclerotic cardiovascular disease (ASCVD) caused over 4&#160;million deaths annually [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Coronary artery disease (CAD), a key contributor to CVD, affected 154&#160;million people globally in 2016, accounting for 32.7% of the CVD burden and 2.2% of the total disease burden. Despite medical advances, CAD remains a leading cause of death and a major healthcare challenge [<xref ref-type="bibr" rid="CR5">5</xref>]. In Latin America, CAD is responsible for 35% of all deaths [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par6">Beyond its high mortality rate, Disability-Adjusted Life Years (DALYs) linked to CVD rose from 279.8&#160;million to 393.1&#160;million over the same period [<xref ref-type="bibr" rid="CR7">7</xref>]. The economic burden of CVDs is also substantial; for instance, the US incurred total costs of $555&#160;billion by 2015, with projections reaching $1.1 trillion by 2035. In low- and middle-income countries, CVD-related costs totaled $3.7 trillion between 2011 and 2015 [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Specifically, CAD contributes 185&#160;million DALYs and imposes a significant financial strain, with annual patient costs often exceeding per capita health expenditures. Pooled direct costs range from 4.9 to 137.8% of gross domestic product per capita, averaging 21.7%, underscoring both the economic burden and regional disparities [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par7">Among modifiable risk factors for CVD, dyslipidemia is one of the most significant. Hypercholesterolemia, particularly elevated levels of low-density lipoprotein cholesterol (LDL-C), is highly prevalent and is a primary contributor to ASCVD [<xref ref-type="bibr" rid="CR10">10</xref>]. LDL-C triggers atherosclerosis via arterial lipoprotein retention. Subsequently, Ox-LDL aggravates the process through endothelial dysfunction and plaque destabilization, heightening thrombotic risk [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. This condition is widespread, for instance, World Health Organization estimates from 2020 indicate that hypercholesterolemia presented a prevalence of 54% in Europe and 48% in the Americas [<xref ref-type="bibr" rid="CR13">13</xref>]. Elevated LDL-C is particularly concerning in patients with prior cardiovascular events due to their higher risk of recurrence, morbidity, and mortality [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par8">Lipid-lowering therapies (LLT) are essential for controlling LDL-C levels and preventing CVDs. Statins remain the cornerstone of LLT; however, newer pharmacological classes, such as proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), have also shown significant success in reducing cardiovascular events [<xref ref-type="bibr" rid="CR15">15</xref>]. Despite the evidence supporting these therapies and their effectiveness in reducing CVDs, target achievement rates range between 31.1% and 54.0% [<xref ref-type="bibr" rid="CR16">16</xref>&#8211;<xref ref-type="bibr" rid="CR18">18</xref>]. Consistent with global findings, the achievement rate of LDL-C goals among Colombian patients ranges between 43.5% and 56% [<xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref>]. Notably, the PURE study, which enrolled 153,996 patients from 17 countries, demonstrated a low use of medications for secondary prevention in CAD, including statins (16.7%), with especially low rates in middle- and low-income countries (26% and 4.5%, respectively) [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par9">LDL-C goals have become increasingly stringent with successive updates to the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines. Between 2011 and 2019, the target LDL-C level for very high cardiovascular risk (CVR) patients was lowered from below 70&#160;mg/dL to below 55&#160;mg/dL to optimize health outcomes in this population [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Despite these recommendations, recent studies report that only about 20% of patients achieve the LDL-C goal established in the 2019 guideline [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par10">Accordingly, evaluating patients at very high CVR in Colombia remains essential to better understand their clinical characteristics and lipid control dynamics. The EDHIPO MARCA (<bold>E</bold>valuaci&#243;n <bold>D</bold>e adherencia a la terapia <bold>HIPO</bold>lipemiante en pacientes de <bold>M</bold>uy <bold>A</bold>lto <bold>R</bold>iesgo <bold>CA</bold>rdiovascular) Registry is a national initiative that evaluates the achievement of LDL-C goals in patients classified as very high CVR due to the presence of CAD [<xref ref-type="bibr" rid="CR27">27</xref>] undergoing LLT, according to the ESC/EAS guidelines published in 2011, 2016, and 2019, across various healthcare institutions nationwide. Therefore, our study provides valuable insights into lipid management practices at both national and Latin American regional levels (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par11">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Central figure</p></caption><graphic id="d33e653" position="float" orientation="portrait" xlink:href="12944_2025_2657_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec2"><title>Methods and material</title><sec id="Sec3"><title>Study design</title><p id="Par12">The EDHIPO MARCA Registry is a retrospective, descriptive, and multicenter study designed to evaluate LDL-C goal achievement and the use of LLT in patients at very high CVR due to established CAD. As defined by the 2019 ESC/EAS guidelines, very high CVR includes individuals with documented ASCVD, either clinical or unequivocal on imaging [<xref ref-type="bibr" rid="CR3">3</xref>]. Accordingly, patients were included based on two criteria: those with angiographic evidence of multivessel coronary disease involving&#8201;&gt;50% stenosis in two major epicardial arteries fulfilled the imaging definition of ASCVD. In patients with &lt;50% stenosis, inclusion required a clinical indication for coronary angiogram such as non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), unstable angina or stable angina, which are explicitly included in the ESC/EAS definition of very high CVR.</p><p id="Par13">The study reviewed coronary angiogram reports and medical records from multiple high-complexity reference institutions in Colombia. LDL-C goal attainment was assessed across three specific periods&#8212;2011&#8211;2012, 2016&#8211;2017, and 2021&#8211;2022&#8212;corresponding to the updates of ESC/EAS guidelines (2011, 2016, and 2019, respectively). The study aimed to assess each guideline update along with the following year; however, for the 2019 guideline, the subsequent year was 2020, when the COVID-19 pandemic hindered outpatient follow-up in this population. Therefore, we included the period 2021&#8211;2022 instead. Patients were included if they had clinically or imaging-confirmed CAD. Medical follow-up records reporting LDL-C levels for up to one-year after coronary angiogram were assessed. Patients with at least one follow-up record were included, with a maximum of four follow-up assessments per patient. Follow-up windows after coronary angiogram were categorized into 3-month intervals for analysis: 1&#160;day to 3 months, 3 months and 1&#160;day to 6 months, 6 months and 1&#160;day to 9 months, and 9 months and 1&#160;day to 12 months.</p></sec><sec id="Sec4"><title>Study population and setting</title><p id="Par14">The study population included adult patients who attended healthcare institutions with certified interventional cardiology services participating in the EDHIPO MARCA Registry, conducted in various cities and regions throughout Colombia. The registry was coordinated by the Centro de Investigaciones Cl&#237;nicas of Fundaci&#243;n Valle del Lili. Eligible patients met the following criteria:<list list-type="alpha-lower"><list-item><p id="Par15">Documented CAD, confirmed either clinically or by coronary angiogram performed in 2011, 2012, 2016, 2017, 2021, or 2022, for any indication;</p></list-item><list-item><p id="Par16">At least one reported lipid panel, including LDL-C, within 12 months following angiogram; and</p></list-item><list-item><p id="Par17">Documented prescription of LLT at follow up.</p></list-item></list></p><p id="Par18">LDL-C was measured directly or estimated using the Friedewald Eq.&#160;[<xref ref-type="bibr" rid="CR28">28</xref>]. When both values were available, the direct measurement was prioritized. If the same patient underwent two coronary angiograms in a single year, only the first was considered. Exclusion criteria included patients requiring dialysis for chronic kidney disease or with uncontrolled hypothyroidism at the time of angiogram, both due to their potential impact on lipid metabolism.</p></sec><sec id="Sec5"><title>Data collection</title><p id="Par19">Data were retrospectively extracted from medical records at each participating institution, covering sociodemographic characteristics, medical history, coronary angiogram results, lipid profile and LLT. Data collection was conducted using case report forms (CRFs) digitized in the Research Electronic Data Capture (REDCap) system, ensuring participant anonymity and data security. Follow-up information was collected at 3-month intervals over a 12-month period.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par20">A descriptive initial analysis was performed on baseline characteristics and achievement of LDL-C goals as defined in the 2011, 2016, and 2019 ESC/EAS guidelines. This analysis corresponds to an assessment of the first 1,788 patients, based on a review of 10,872 medical records as of the data cutoff. The study uses a non-probabilistic convenience sampling approach, with an expected total sample size of 5,000 patients, distributed across at least 10 high-complexity institutions in Colombia. Each participating center is expected to contribute approximately 300 to 500 patients, depending on the availability of eligible cases. LDL-C goals were defined according to the respective ESC/EAS guidelines periods: &lt;70&#160;mg/dL for the 2011 and 2016 guidelines, and &lt;55&#160;mg/dL for the 2019 guideline. Frequencies and proportions were used for categorical variables, while measures of central tendency and dispersion were reported for quantitative variables. Normality of distribution was assessed using the Kolmogorov-Smirnov test. All statistical analyses were conducted using RStudio 2024.12.0&#8201;+&#8201;467 (R Foundation for Statistical Computing, Vienna, Austria). Figures were created using Python (matplotlib library, version 3.x).</p></sec></sec><sec id="Sec7"><title>Results</title><p id="Par21">For this analysis, 1,788 patients from 11 medical institutions in Colombia were included. The median age was 66 years (IQR: 59&#8211;74), with a similar age distribution across all guidelines-based groups. Most of the population was male, comprising 70.7% of the sample (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par22">Regarding comorbidities, hypertension (HTN) was the most prevalent, affecting 67.5% of patients overall. Its prevalence was particularly high among patients in the 2011 ESC/EAS guideline group, where 75.8% had HTN. The overall prevalence was 40.8% for overweight, 18.9% for obesity, and 27.4% for diabetes mellitus (DM). Overweight increased from 28.6% in the 2011 group to 33.3% in the 2016 group, then declined to 27.9% in the 2019 cohort. Obesity rose steadily from 12.1% in the 2011 group to 14.9% and 20.9% in the 2016 and 2019 cohorts respectively. DM increased from 22% in the 2011 group to 29.9% in the 2016 group, before decreasing to 26.4% in the 2019 cohort. Comorbidities with lower frequencies are described in Additional file 1, Table <xref rid="MOESM1" ref-type="media">S1</xref>.</p><p id="Par23">Among the clinical indications for performing coronary angiogram, NSTEMI had the highest representation (29.1%), with a slight increase in the 2011 guideline group (35.2%). Unstable angina followed in frequency (24.9%), also peaking in the 2011 guideline group (35.2%). STEMI accounted for 20.7%, with some fluctuation across guidelines and being higher (23.6%) in the 2016 guideline cohort. Stable angina represented 12.9% of the indications, showing greater variation and an increase to 18.3% in the 2016 guideline group (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par24">LLT prescribed at discharge after the coronary angiogram varied across the different guidelines periods evaluated. Statins were the most frequently prescribed LLT, with an overall usage of 84.1%, reaching a peak of 89.3% in the 2016 guideline group. High-intensity statin regimens were prescribed in 91% of cases, following an upward trend and peaking at 96.9% under the 2019 guideline period. Ezetimibe use was limited overall (5.5%) but increased in the 2019 guideline group (7.9%). Fibrates were prescribed to 1.2% of patients, predominantly in the 2019 guideline group (1.3%). PCSK9i were rarely used, with a prescription rate of 0.4% exclusively under the 2019 guideline group. Notably, 4.7% of patients were discharged without any LLT, with the highest proportion observed in the 2019 guideline cohort (5.7%) (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par25">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics of patients stratified by ESC/EAS guidelines groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="left" rowspan="2" colspan="1">Overall, <italic toggle="yes">N</italic>&#8201;=&#8201;1,788</th><th align="left" colspan="3" rowspan="1">ESC/EAS Guidelines Groups</th></tr><tr><th align="left" colspan="1" rowspan="1">2011, <italic toggle="yes">N</italic>&#8201;=&#8201;91</th><th align="left" colspan="1" rowspan="1">2016, <italic toggle="yes">N</italic>&#8201;=&#8201;475</th><th align="left" colspan="1" rowspan="1">2019, <italic toggle="yes">N</italic>&#8201;=&#8201;1,222</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1">66 (59,74)</td><td align="left" colspan="1" rowspan="1">63 (56,70)</td><td align="left" colspan="1" rowspan="1">68 (59,75)</td><td align="left" colspan="1" rowspan="1">66 (59,75)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Male</italic>
</td><td align="left" colspan="1" rowspan="1">1,265 (70.7%)</td><td align="left" colspan="1" rowspan="1">68 (74.7%)</td><td align="left" colspan="1" rowspan="1">327 (68.8%)</td><td align="left" colspan="1" rowspan="1">870 (71.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Female</italic>
</td><td align="left" colspan="1" rowspan="1">523 (29.3%)</td><td align="left" colspan="1" rowspan="1">23 (25.3%)</td><td align="left" colspan="1" rowspan="1">148 (31.2%)</td><td align="left" colspan="1" rowspan="1">352 (28.8%)</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Comorbidities</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">HTN</td><td align="left" colspan="1" rowspan="1">1,207 (67.5%)</td><td align="left" colspan="1" rowspan="1">69 (75.8%)</td><td align="left" colspan="1" rowspan="1">343 (72.2%)</td><td align="left" colspan="1" rowspan="1">795 (65.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Overweight</td><td align="left" colspan="1" rowspan="1">729 (40.8%)</td><td align="left" colspan="1" rowspan="1">26 (28.6%)</td><td align="left" colspan="1" rowspan="1">158 (33.3%)</td><td align="left" colspan="1" rowspan="1">341 (27.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">DM</td><td align="left" colspan="1" rowspan="1">490 (27.4%)</td><td align="left" colspan="1" rowspan="1">20 (22%)</td><td align="left" colspan="1" rowspan="1">142 (29.9%)</td><td align="left" colspan="1" rowspan="1">328 (26.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Obesity</td><td align="left" colspan="1" rowspan="1">338 (18.9%)</td><td align="left" colspan="1" rowspan="1">11 (12.1%)</td><td align="left" colspan="1" rowspan="1">71 (14.9%)</td><td align="left" colspan="1" rowspan="1">256 (20.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">HF</td><td align="left" colspan="1" rowspan="1">309 (17.3%)</td><td align="left" colspan="1" rowspan="1">5 (5.5%)</td><td align="left" colspan="1" rowspan="1">76 (16%)</td><td align="left" colspan="1" rowspan="1">228 (18.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">LVEF (%)</italic>
</td><td align="left" colspan="1" rowspan="1">42 (32, 55.8)</td><td align="left" colspan="1" rowspan="1">30 (20, 40)</td><td align="left" colspan="1" rowspan="1">45 (37, 55)</td><td align="left" colspan="1" rowspan="1">40 (30, 57)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypothyroidism</td><td align="left" colspan="1" rowspan="1">293 (16.4%)</td><td align="left" colspan="1" rowspan="1">12 (15.4%)</td><td align="left" colspan="1" rowspan="1">64 (13.5%)</td><td align="left" colspan="1" rowspan="1">215 (17.6%)</td></tr><tr><td align="left" colspan="1" rowspan="1">CKD</td><td align="left" colspan="1" rowspan="1">154 (8.6%)</td><td align="left" colspan="1" rowspan="1">9 (9.9%)</td><td align="left" colspan="1" rowspan="1">50 (10.5%)</td><td align="left" colspan="1" rowspan="1">95 (7.8%)</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Coronary angiogram Indication</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">NSTEMI</td><td align="left" colspan="1" rowspan="1">520 (29.1%)</td><td align="left" colspan="1" rowspan="1">32 (35.2%)</td><td align="left" colspan="1" rowspan="1">132 (27.8%)</td><td align="left" colspan="1" rowspan="1">356 (29.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Unstable Angina</td><td align="left" colspan="1" rowspan="1">445 (24.9%)</td><td align="left" colspan="1" rowspan="1">32 (35.2%)</td><td align="left" colspan="1" rowspan="1">108 (22.7%)</td><td align="left" colspan="1" rowspan="1">305 (25%)</td></tr><tr><td align="left" colspan="1" rowspan="1">STEMI</td><td align="left" colspan="1" rowspan="1">371 (20.7%)</td><td align="left" colspan="1" rowspan="1">16 (17.6%)</td><td align="left" colspan="1" rowspan="1">112 (23.6%)</td><td align="left" colspan="1" rowspan="1">243 (19.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Stable Angina</td><td align="left" colspan="1" rowspan="1">231 (12.9%)</td><td align="left" colspan="1" rowspan="1">6 (6.6%)</td><td align="left" colspan="1" rowspan="1">87 (18.3%)</td><td align="left" colspan="1" rowspan="1">138 (11.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Other</td><td align="left" colspan="1" rowspan="1">221 (12.4%)</td><td align="left" colspan="1" rowspan="1">5 (5.5%)</td><td align="left" colspan="1" rowspan="1">36 (7.6%)</td><td align="left" colspan="1" rowspan="1">180 (14.7%)</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>LLT at discharge</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Statins</td><td align="left" colspan="1" rowspan="1">1,504 (84.1%)</td><td align="left" colspan="1" rowspan="1">62 (68.1%)</td><td align="left" colspan="1" rowspan="1">424 (89.3%)</td><td align="left" colspan="1" rowspan="1">1,018 (83.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">High-intensity*</italic>
</td><td align="left" colspan="1" rowspan="1">1,369 (91%)</td><td align="left" colspan="1" rowspan="1">10 (16.1%)</td><td align="left" colspan="1" rowspan="1">373 (88%)</td><td align="left" colspan="1" rowspan="1">986 (96.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Moderate-intensity*</italic>
</td><td align="left" colspan="1" rowspan="1">120 (8%)</td><td align="left" colspan="1" rowspan="1">45 (72.6%)</td><td align="left" colspan="1" rowspan="1">44 (10.4%)</td><td align="left" colspan="1" rowspan="1">31 (3%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Low-intensity*</italic>
</td><td align="left" colspan="1" rowspan="1">7 (0.5%)</td><td align="left" colspan="1" rowspan="1">6 (9.7%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">1 (0.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">No recorded dose</italic>
</td><td align="left" colspan="1" rowspan="1">8 (0.5%)</td><td align="left" colspan="1" rowspan="1">1 (1.6%)</td><td align="left" colspan="1" rowspan="1">7 (1.7%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Fibrates</td><td align="left" colspan="1" rowspan="1">21 (1.2%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">5 (1.1%)</td><td align="left" colspan="1" rowspan="1">16 (1.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ezetimibe</td><td align="left" colspan="1" rowspan="1">99 (5.5%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">3 (0.6%)</td><td align="left" colspan="1" rowspan="1">96 (7.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">PCSK9i</td><td align="left" colspan="1" rowspan="1">5 (0.3)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">5 (0.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">No LLT</td><td align="left" colspan="1" rowspan="1">84 (4.7%)</td><td align="left" colspan="1" rowspan="1">3 (3.3%)</td><td align="left" colspan="1" rowspan="1">11 (2.3%)</td><td align="left" colspan="1" rowspan="1">70 (5.7%)</td></tr></tbody></table><table-wrap-foot><p>Values are presented in n (%) and median (IQR)</p><p>CKD: Chronic Kidney Disease, DM: Diabetes Mellitus, ESC/EAS: European Society of Cardiology/European Atherosclerosis Society, HF: Heart Failure, HTN: Hypertension, LLT: Lipid-Lowering Therapy, LVEF: Left Ventricular Ejection Fraction, NSTEMI: Non-ST Elevation Myocardial Infarction, PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitors, STEMI: ST Elevation Myocardial Infarction</p><p>*High-intensity statins: atorvastatin&#8201;&#8805;40&#160;mg/day, rosuvastatin&#8201;&#8805;20&#160;mg/day. Moderate-intensity statins: atorvastatin&#8201;&lt;40&#160;mg/day, rosuvastatin&#8201;&lt;20&#160;mg/day, simvastatin&#8201;&#8805;20&#160;mg/day, lovastatin&#8201;&#8805;40&#160;mg/day. Low-intensity statins: simvastatin&#8201;&lt;20&#160;mg/day, lovastatin&#8201;&lt;40&#160;mg/day, pravastatin 20&#160;mg</p><p><bold>Missing Data Notes</bold>: Obesity and overweight data were missing for 98 patients because BMI could not be calculated due to the absence of weight and/or height records in medical history (24 in 2011, 48 in 2016, and 26 in 2019). LVEF was not reported for 19 patients due to the absence of this information in medical history (0 in 2011, 3 in 2016, and 16 in 2019)</p></table-wrap-foot></table-wrap>
</p><p id="Par26">At the final follow-up visit (median time: 6.8 months; IQR 3.7&#8211;9.9), 36.6% (95% CI: 34.3&#8211;38.8%) of patients had achieved LDL-C goals. The highest proportion was observed in the ESC/EAS 2016 group (42.3%, 95% CI: 37.9&#8211;46.8%), followed by the 2019 guideline group (36.2%, 95% CI: 33.5&#8211;38.9%). Among patients with one follow-up (<italic toggle="yes">n</italic>&#8201;=&#8201;1,084), 32.9% achieved LDL-C goals, with the highest proportion in the ESC/EAS 2016 group (41.1%). With two follow-ups (<italic toggle="yes">n</italic>&#8201;=&#8201;503), 41% of patients achieved goals, with the ESC/EAS 2019 group showing the greatest improvement (42.3%). For patients with three (<italic toggle="yes">n</italic>&#8201;=&#8201;176) and four (<italic toggle="yes">n</italic>&#8201;=&#8201;25) follow-ups, the overall proportions achieving LDL-C goals were 45.5% and 44%, respectively. When assessed according to the ESC/EAS 2019 guideline, these proportions were 44.7% and 44.4%, respectively. A detailed breakdown of these findings is provided in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par27">The relative change in LDL-C, defined as the difference between the last and first available measurements during follow-up after coronary angiogram, became more pronounced with a higher number of follow-up measurements across the total population. This pattern was observed in both the 2011 and 2019 guidelines cohorts. In the 2011 guideline group, the relative change indicated a reduction of 0.3% after two follow-ups, which became more marked after three follow-ups, reaching 7.7%. In the 2019 guideline cohort, the reduction progressed from 5.6% after two follow-ups to 9.8% after three and reached 31.1% after four follow-ups &#8212; representing the most substantial LDL-C reduction among all cohorts (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par28">Among the total cohort, overall goal achievement ranged from 33.1% in the first follow-up window (first trimester post-coronary angiogram) to 37% and 36.7% in the third and fourth windows, respectively. Patients following the ESC/EAS 2016 guideline consistently demonstrated the highest achievement rates across all follow-up windows, with 44.2% in the first window, 45.3% in the second, 40.2% in the third, and 40.6% in the fourth. In contrast, patients under the ESC/EAS 2011 guideline had the lowest achievement rates, particularly in the later windows, with values as low as 6.7% in the final follow-up window. Achievement for the ESC/EAS 2019 group was moderate and like the overall cohort, ranging from 30.4 to 38.6% (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par29">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>LDL-C goal achievement by guideline group, follow-up number and timing</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="left" rowspan="2" colspan="1">Overall, <italic toggle="yes">N</italic>&#8201;=&#8201;1,788</th><th align="left" colspan="3" rowspan="1">ESC/EAS Guidelines Groups</th></tr><tr><th align="left" colspan="1" rowspan="1">
<bold>2011, </bold>
<bold><italic toggle="yes">N</italic></bold>
<bold>&#8201;=&#8201;91</bold>
</th><th align="left" colspan="1" rowspan="1">
<bold>2016, </bold>
<bold><italic toggle="yes">N</italic></bold>
<bold>&#8201;=&#8201;475</bold>
</th><th align="left" colspan="1" rowspan="1"><bold>2019, </bold><bold><italic toggle="yes">N</italic></bold><bold>&#8201;=&#8201;1</bold>,<bold>222</bold></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">LDL-C Goal Achievement</td><td align="left" colspan="1" rowspan="1">654 (36.6%)</td><td align="left" colspan="1" rowspan="1">11 (12.1%)</td><td align="left" colspan="1" rowspan="1">201 (42.3%)</td><td align="left" colspan="1" rowspan="1">442 (36.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Follow-up, months</td><td align="left" colspan="1" rowspan="1">6.8 (3.7, 9.9)</td><td align="left" colspan="1" rowspan="1">6.8 (3.9, 9.9)</td><td align="left" colspan="1" rowspan="1">6.6 (4.1, 9.6)</td><td align="left" colspan="1" rowspan="1">7.0 (3.5, 10.1)</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Target achievement by number of follow-ups</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Achievement with 1 follow-up</td><td align="left" colspan="1" rowspan="1">357/1,084 (32.9%)</td><td align="left" colspan="1" rowspan="1">6/60 (10%)</td><td align="left" colspan="1" rowspan="1">137/333 (41.1%)</td><td align="left" colspan="1" rowspan="1">214/691 (31%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Achievement with 2 follow-ups</td><td align="left" colspan="1" rowspan="1">206/503 (41%)</td><td align="left" colspan="1" rowspan="1">4/21 (19%)</td><td align="left" colspan="1" rowspan="1">41/101 (40.6%)</td><td align="left" colspan="1" rowspan="1">161/381 (42.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Relative change in LDL-C (%) *</td><td align="left" colspan="1" rowspan="1">-2.6 (-23.1, 18.5,)</td><td align="left" colspan="1" rowspan="1">-0.3 (-15.3, 27.4)</td><td align="left" colspan="1" rowspan="1">3.3 (-15.2, 29.9)</td><td align="left" colspan="1" rowspan="1">-5.6 (-26.9, 16.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Achievement with 3 follow-ups</td><td align="left" colspan="1" rowspan="1">80/176 (45.5%)</td><td align="left" colspan="1" rowspan="1">0/9 (0%)</td><td align="left" colspan="1" rowspan="1">21/35 (60%)</td><td align="left" colspan="1" rowspan="1">59/132 (44.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Relative change in LDL-C (%) *</td><td align="left" colspan="1" rowspan="1">-2.9 (-32.7, 16.8)</td><td align="left" colspan="1" rowspan="1">-7.7 (-10.5, 5.5)</td><td align="left" colspan="1" rowspan="1">8.1 (-10.5, 27.1)</td><td align="left" colspan="1" rowspan="1">-9.8 (-40.5, 15.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Achievement with 4 follow-ups</td><td align="left" colspan="1" rowspan="1">11/25 (44%)</td><td align="left" colspan="1" rowspan="1">1/1 (100%) **</td><td align="left" colspan="1" rowspan="1">2/6 (33.3%)</td><td align="left" colspan="1" rowspan="1">8/18 (44.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Relative change in LDL-C(%) *</td><td align="left" colspan="1" rowspan="1">-20.6 (-35.1, -3.1)</td><td align="left" colspan="1" rowspan="1">-20.5 **</td><td align="left" colspan="1" rowspan="1">-9.9 (-19.6, 3.3)</td><td align="left" colspan="1" rowspan="1">-31.1 (-37.4, -7.2)</td></tr><tr><td align="left" colspan="5" rowspan="1">
<bold>Target achievement by timing of last follow-up</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Follow-up window 1 (1&#160;day to 3 months)</td><td align="left" colspan="1" rowspan="1">114/344 (33.1%)</td><td align="left" colspan="1" rowspan="1">4/17 (23.5%)</td><td align="left" colspan="1" rowspan="1">34/77 (44.2%)</td><td align="left" colspan="1" rowspan="1">76/250 (30.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Follow-up window 2 (3 months and 1&#160;day to 6 months)</td><td align="left" colspan="1" rowspan="1">159/420 (37.9%)</td><td align="left" colspan="1" rowspan="1">2/21 (9.5%)</td><td align="left" colspan="1" rowspan="1">58/128 (45.3%)</td><td align="left" colspan="1" rowspan="1">99/271 (36.5%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Follow-up window 3 (6 months and 1&#160;day to 9 months)</td><td align="left" colspan="1" rowspan="1">173/468 (37%)</td><td align="left" colspan="1" rowspan="1">3/23 (1.3%)</td><td align="left" colspan="1" rowspan="1">51/127 (40.2%)</td><td align="left" colspan="1" rowspan="1">119/318 (37.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Follow-up window 4 (9 months and 1&#160;day to 12 months)</td><td align="left" colspan="1" rowspan="1">208/566 (36.7%)</td><td align="left" colspan="1" rowspan="1">2/30 (6.7%)</td><td align="left" colspan="1" rowspan="1">58/143 (40.6%)</td><td align="left" colspan="1" rowspan="1">148/383 (38.6%)</td></tr></tbody></table><table-wrap-foot><p>Values are presented in n (%) or median (IQR)</p><p>ESC/EAS: European Society of Cardiology/European Atherosclerosis Society, LDL-C: low-density lipoprotein cholesterol, IQR: Interquartile Range</p><p>The goal proposed by the ESC/EAS according to the 2011 update (years 2011 and 2012) and the 2016 update (years 2016 and 2017) is &lt;70&#160;mg/dL, while for the 2019 update (years 2021 and 2022), it is &lt;55&#160;mg/dL</p><p>* Relative change= (Last follow-up LDL-C&#8201;&#8722;&#8201;First follow-up LDL-C) / First follow-up LDL-C &#215; 100</p><p>** Only one patient had 4 four follows in the 2011 cohort</p></table-wrap-foot></table-wrap>
</p><p id="Par30">Regarding LDL-C levels, the mean LDL-C in the total population at the end of follow-up was 73.5&#160;mg/dL (&#177;&#8201;33.8). Differences were observed between groups, with the highest level in the 2011 guideline group (95.8&#160;mg/dL&#8201;&#177;&#8201;31.3) and the lowest in the 2019 guideline group (69.5&#160;mg/dL&#8201;&#177;&#8201;32.3). Among patients who achieved LDL-C goals, the mean LDL-C level was 44.4&#160;mg/dL&#8201;&#177;&#8201;12.4, with the lowest concentration observed in those treated under the 2019 guideline (41.5&#160;mg/dL&#8201;&#177;&#8201;10.4) and the highest in the 2011 guideline group (52.2&#160;mg/dL&#8201;&#177;&#8201;13.6). In patients who did not reach LDL-C goals, the mean LDL-C concentration was 90.3&#160;mg/dL, with the highest levels appearing in both 2011 (101.8&#160;mg/dL) and 2016 guidelines groups (100.9&#160;mg/dL), while the lowest concentration was found in the 2019 group (85.4&#160;mg/dL) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>).</p><p id="Par31">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>LDL-C levels based on goal achievement at the end of follow-up. ESC/EAS: European Society of Cardiology/European Atherosclerosis Society, LDL-C: low-density lipoprotein cholesterol</p></caption><graphic id="d33e1369" position="float" orientation="portrait" xlink:href="12944_2025_2657_Fig2_HTML.jpg"/></fig>
</p><p id="Par32">Across the guidelines groups, statins remained the most prescribed medication at the end of follow-up, covering 99.1% of cases. High-intensity statin regimens were prescribed in 89.8% of patients, with the highest proportion observed in the 2019 guideline group (95.2%). Atorvastatin was the most widely used statin overall (57.1%), followed by rosuvastatin (38.7%). In the 2011 guideline group, statin use reached 100%, with lovastatin as the predominant choice (58.2%), followed by atorvastatin (31.9%). By 2016, 99.6% of patients received statins, with atorvastatin (85.2%) and rosuvastatin (13.1%) as the main choices. Lovastatin use dropped to just one patient (0.2%) in the 2016 guideline group. In the 2019 guideline cohort, statin prescriptions remained high at 98.9%, though atorvastatin use declined to 48% as rosuvastatin increased to 51.2% (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par33">Regarding dosage patterns, the most common statins prescribed were atorvastatin and rosuvastatin, which showed distinct temporal trends. Among patients receiving treatment before the coronary angiogram, atorvastatin 40&#160;mg/day was the most frequently used dose (68.7%), though its use declined at discharge (47.0%) and then rose again at follow-up (56.1%). In contrast, atorvastatin 80&#160;mg/day showed a marked increase from pre-coronary angiogram (10.9%) to discharge (47.8%), followed by a reduction at follow-up (36.3%). For rosuvastatin, the highest dose (40&#160;mg/day) was already common before the angiogram (67.1%) and increased progressively at discharge (79.9%) and follow-up (82.5%). Dosing patterns for other statins are detailed in Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>, and non-statin LLT are presented in Table <xref rid="MOESM1" ref-type="media">S2</xref> of the supplementary material.</p><p id="Par34">Among non-statin LLT, ezetimibe was the most frequently prescribed (17.2% overall) at the end of follow-up, with an uptake at 4.4% in 2011, 3.8% in 2016, and 23.4% in 2019. Fibrates were infrequently prescribed, accounting for 2.2% of overall cases, with fenofibrate being the most common fibrate in all evaluated guidelines groups (100%, 63.6% and 96.4% for 2011, 2016 and 2019 ESC/EAS guidelines, respectively). PCSK9i were only prescribed in the 2019 guideline cohort, accounting for 2.2% of those patients and 1.5% of the total population, with alirocumab being the most prescribed (55.6%). Omega-3 fatty acids were minimally prescribed, totaling only 0.5% (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par35">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>LLT at the end of follow-up across ESC/EAS guidelines periods</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="left" rowspan="2" colspan="1">Overall, <italic toggle="yes">N</italic>&#8201;=&#8201;1,788</th><th align="left" colspan="3" rowspan="1">ESC/EAS Guidelines Groups</th></tr><tr><th align="left" colspan="1" rowspan="1">2011, <italic toggle="yes">N</italic>&#8201;=&#8201;91</th><th align="left" colspan="1" rowspan="1">2016, <italic toggle="yes">N</italic>&#8201;=&#8201;475</th><th align="left" colspan="1" rowspan="1">2019, <italic toggle="yes">N</italic>&#8201;=&#8201;1,222</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Statins</td><td align="left" colspan="1" rowspan="1">1,772 (99.1%)</td><td align="left" colspan="1" rowspan="1">91 (100%)</td><td align="left" colspan="1" rowspan="1">473 (99.6%)</td><td align="left" colspan="1" rowspan="1">1,208 (98.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">High-intensity*</italic>
</td><td align="left" colspan="1" rowspan="1">1,591 (89.8%)</td><td align="left" colspan="1" rowspan="1">24 (26.4%)</td><td align="left" colspan="1" rowspan="1">417 (88.2%)</td><td align="left" colspan="1" rowspan="1">1,150 (95.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Moderate-intensity*</italic>
</td><td align="left" colspan="1" rowspan="1">155 (8.7%)</td><td align="left" colspan="1" rowspan="1">56 (61.5%)</td><td align="left" colspan="1" rowspan="1">44 (9.3%)</td><td align="left" colspan="1" rowspan="1">55 (4.6%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Low-intensity*</italic>
</td><td align="left" colspan="1" rowspan="1">11 (0.6%)</td><td align="left" colspan="1" rowspan="1">8 (8.8%)</td><td align="left" colspan="1" rowspan="1">1 (0.2%)</td><td align="left" colspan="1" rowspan="1">2 (0.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">No recorded dose</italic>
</td><td align="left" colspan="1" rowspan="1">15 (0.8%)</td><td align="left" colspan="1" rowspan="1">3 (3.3%)</td><td align="left" colspan="1" rowspan="1">11 (2.3%)</td><td align="left" colspan="1" rowspan="1">1 (0.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Atorvastatin</italic>
</td><td align="left" colspan="1" rowspan="1">1,012 (57.1%)</td><td align="left" colspan="1" rowspan="1">29 (31.9%)</td><td align="left" colspan="1" rowspan="1">403 (85.2%)</td><td align="left" colspan="1" rowspan="1">580 (48%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Rosuvastatin</italic>
</td><td align="left" colspan="1" rowspan="1">686 (38.7%)</td><td align="left" colspan="1" rowspan="1">6 (6.6%)</td><td align="left" colspan="1" rowspan="1">62 (13.1%)</td><td align="left" colspan="1" rowspan="1">618 (51.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Lovastatin</italic>
</td><td align="left" colspan="1" rowspan="1">55 (3.1%)</td><td align="left" colspan="1" rowspan="1">53 (58.2%)</td><td align="left" colspan="1" rowspan="1">1 (0.2%)</td><td align="left" colspan="1" rowspan="1">1 (0.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Simvastatin</italic>
</td><td align="left" colspan="1" rowspan="1">18 (1%)</td><td align="left" colspan="1" rowspan="1">3 (3.3%)</td><td align="left" colspan="1" rowspan="1">7 (1.5%)</td><td align="left" colspan="1" rowspan="1">8 (0.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Pravastatin</italic>
</td><td align="left" colspan="1" rowspan="1">1 (0.1%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">1 (0.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Ezetimibe</td><td align="left" colspan="1" rowspan="1">308 (17.2%)</td><td align="left" colspan="1" rowspan="1">4 (4.4%)</td><td align="left" colspan="1" rowspan="1">18 (3.8%)</td><td align="left" colspan="1" rowspan="1">286 (23.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Fibrates</td><td align="left" colspan="1" rowspan="1">40 (2.2%)</td><td align="left" colspan="1" rowspan="1">1 (1.1%)</td><td align="left" colspan="1" rowspan="1">11 (2.3%)</td><td align="left" colspan="1" rowspan="1">28 (2.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Fenofibrate</italic>
</td><td align="left" colspan="1" rowspan="1">35 (87.5%)</td><td align="left" colspan="1" rowspan="1">1 (100%)</td><td align="left" colspan="1" rowspan="1">7 (63.6%)</td><td align="left" colspan="1" rowspan="1">27 (96.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Ciprofibrate</italic>
</td><td align="left" colspan="1" rowspan="1">3 (7.5%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">2 (18.2%)</td><td align="left" colspan="1" rowspan="1">1 (3.6%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Gemfibrozil</italic>
</td><td align="left" colspan="1" rowspan="1">2 (5%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">2 (18.2%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">PCSK9i</td><td align="left" colspan="1" rowspan="1">27 (1.5%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">27 (2.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Alirocumab</italic>
</td><td align="left" colspan="1" rowspan="1">15 (55.6%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">15 (55.6%)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Evolocumab</italic>
</td><td align="left" colspan="1" rowspan="1">12 (44.4%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">12 (44.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Omega-3 Fatty Acids</td><td align="left" colspan="1" rowspan="1">9 (0.5%)</td><td align="left" colspan="1" rowspan="1">2 (2.2%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td align="left" colspan="1" rowspan="1">7 (0.6%)</td></tr></tbody></table><table-wrap-foot><p>Values are presented in n (%)</p><p>ESC/EAS: European Society of Cardiology/European Atherosclerosis Society, PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitors</p><p>* High-intensity statins: atorvastatin&#8201;&#8805;40&#160;mg/day, rosuvastatin&#8201;&#8805;20&#160;mg/day. Moderate-intensity statins: atorvastatin&#8201;&lt;40&#160;mg/day, rosuvastatin&#8201;&lt;20&#160;mg/day, simvastatin&#8201;&#8805;20&#160;mg/day, lovastatin&#8201;&#8805;40&#160;mg/day. Low-intensity statins: simvastatin&#8201;&lt;20&#160;mg/day, lovastatin&#8201;&lt;40&#160;mg/day, pravastatin 20&#160;mg</p></table-wrap-foot></table-wrap>
</p><p id="Par36">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Heatmap of statin utilization by dose and timepoint. Pre-CA: Pre-Coronary Angiogram</p></caption><graphic id="d33e1713" position="float" orientation="portrait" xlink:href="12944_2025_2657_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec8"><title>Discussion</title><p id="Par37">Our study provides a comprehensive evaluation of LDL-C goal achievement in very high CVR Colombian patients. To our knowledge, this is one of the largest studies in Colombia and Latin America assessing this outcome in patients with CAD, offering valuable insights into current national and regional practices. While statins remain the primary LLT, lipid management has gradually expanded with greater use of ezetimibe and PCSK9 inhibitors. However, the implementation of non-statin therapies remains limited, despite their importance in achieving stricter LDL-C targets. Our findings also highlight the role of follow-up frequency in optimizing LLT effectiveness. Despite these considerations, LDL-C goal achievement remains suboptimal.</p><p id="Par38">Our cohort predominantly consisted of elderly patients, consistent with well-established evidence identifying age as a major risk factor for atherosclerosis [<xref ref-type="bibr" rid="CR29">29</xref>]. Studies such as the START registry and DA VINCI study closely align with our findings [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Additionally, the male predominance in our cohort is similar to the sex distribution in those studies [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Men are known to exhibit a higher prevalence and extent of atherosclerotic plaque, while women often present with diffuse disease, complicating diagnosis and potentially lowering its reported prevalence [<xref ref-type="bibr" rid="CR32">32</xref>]. This sex distribution, also observed in Colombian cohorts, appears to have clinical implications, as male patients appear to exhibit higher MACE outcomes [<xref ref-type="bibr" rid="CR33">33</xref>]. Lastly, the high prevalence of HTN, overweight, obesity, and DM in our cohort supports their well-established association with ASCVD [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par39">Discharge after a coronary angiogram is a key moment to optimize LLT management, and it is recommended to initiate high-intensity statins as soon as possible, regardless of baseline LDL-C levels [<xref ref-type="bibr" rid="CR36">36</xref>]. Nevertheless, a significant proportion of patients do not receive this therapy upon discharge, missing a crucial opportunity for secondary prevention [<xref ref-type="bibr" rid="CR37">37</xref>]. In our cohort, 84.1% of patients were prescribed statins at discharge, a higher rate than in a retrospective US study across 12 hospitals, where only 70.8% received statins within 21 days of an acute coronay syndrome (ACS) event. Notably, just 48.9% received high-intensity statins in that study, reflecting significantly lower use [<xref ref-type="bibr" rid="CR38">38</xref>]. Despite high statin prescription rates at discharge, many patients did not reach LDL-C targets, suggesting that factors such as access or adherence may play a role. Nonetheless, the increasing use of high-intensity statins&#8212;peaking in the 2019 guideline group&#8212;likely reflects growing physician awareness and implementation of ESC/EAS recommendations.</p><p id="Par40">At follow-up, most patients in our cohort were also receiving statins, mainly high-intensity regimens, underscoring their central role in long-term lipid management. This aligns with large studies like a Swedish cohort of 26,768 patients with established ASCVD, where statins remained the cornerstone therapy&#8212;used in 82% within 90 days of discharge and 86% after one year [<xref ref-type="bibr" rid="CR39">39</xref>]. In our cohort, statin and high-intensity regimen use were higher&#8212;likely influenced by the inclusion criteria, which required LLT prescription after follow-up angiogram. Nonetheless, both cohorts showed a steady increase in high-intensity statin use, suggesting a broader shift toward improved implementation of the guidelines. Notably, the widespread use of lovastatin in Colombia and its subsequent decline could be related to its initial inclusion in the national healthcare coverage system, followed by the later incorporation of more effective statins that enabled better achievement of LDL-C goals [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par41">A decline in high-dose atorvastatin, simvastatin, and lovastatin use was observed over time. This pattern may reflect clinical adjustments in response to hepatic or muscular adverse effects, prompting physicians to reduce dosing in some patients [<xref ref-type="bibr" rid="CR41">41</xref>]. Notably, 80&#160;mg/day doses of simvastatin and lovastatin were prescribed in some patients. Given that the cohort included individuals treated as early as January 2011, before the FDA&#8217;s warning issued in June of that year, the use of high doses may be explained by the fact that these prescriptions preceded the updated safety recommendations [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par42">Despite guideline consensus supporting ezetimibe and PCSK9i combined with high-intensity statins to improve LDL-C goal achievement, its use remains low in routine care [<xref ref-type="bibr" rid="CR43">43</xref>]. The DA VINCI study, for example, reported that only 9.3% and 1.2% of patients were on ezetimibe or PCSK9i, respectively [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], highlighting the gap between ESC/EAS guidelines recommendations and real-world implementation, particularly in very high CVR populations. These therapies are also underused in Colombia, with a national study showing that only 0.8% of 103,624 eligible patients received ezetimibe [<xref ref-type="bibr" rid="CR45">45</xref>]. Similarly, analysis of government health data identified only 7,431 PCSK9i prescriptions between 2019 and 2021, despite the high prevalence of CVD in the country [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. In contrast, an Italian study found that 74.5% of patients received ezetimibe combination therapy, suggesting that a more structured healthcare system may facilitate its use. In contrast, PCSK9i use remained low, highlighting the global challenge of adopting this newer therapy [<xref ref-type="bibr" rid="CR48">48</xref>]. Nevertheless, part of the limited uptake may also be explained by the inclusion of years prior to PCSK9i availability in our analysis period.</p><p id="Par43">These dynamics may be partly explained by systemic factors such as fragmentation of the healthcare system, disparities between insurance schemes, and out-of-pocket costs, all of which may ultimately impact prescribing practices [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. For instance, a Colombian study reported that 11.3% of elderly patients received at least one potentially inappropriate cardiovascular medication, according to the Beers criteria, which encompass several commonly used drugs in older adults [<xref ref-type="bibr" rid="CR51">51</xref>]. In a separate analysis, 15.9% of patients with CVD had potential prescribing omissions based on STOPP/START criteria [<xref ref-type="bibr" rid="CR52">52</xref>]. These results reveal persistent gaps in the quality of prescribing even for basic cardiovascular therapies, raising concerns about the feasibility of implementing more complex treatment strategies or drug combinations, such as ezetimibe or PCSK9i.</p><p id="Par44">Although statin use was high, with a substantial proportion receiving high-intensity regimens, LDL-C goal achievement at the last follow-up remained relatively low and varied depending on the guideline used, aligning with several reports showing suboptimal LDL-C target attainment worldwide. The START registry reported a target attainment rate of 58.1%, which, although higher than in our study, remained suboptimal. Notably, when applying the more stringent 2019 guideline threshold, this rate dropped to 38%, closely aligning with the proportion observed in our cohort [<xref ref-type="bibr" rid="CR30">30</xref>]. A multicenter cross-sectional study from Portugal involving 8,288 patients with ASCVD reported significantly lower LDL-C goal achievement compared to our findings, with only 18% and 7% of patients meeting the 2016 and 2019 ESC/EAS thresholds, respectively [<xref ref-type="bibr" rid="CR53">53</xref>]. Similarly, a study of 650 post-myocardial infarction patients found that just 34% and 11.7% reached LDL-C goals of 70&#160;mg/dL and 55&#160;mg/dL, respectively&#8212;both lower than in our study [<xref ref-type="bibr" rid="CR54">54</xref>]. Comparable findings were reported in the INTERASPIRE study, an international study of patients with coronary heart disease conducted across 14 countries. Despite 86% receiving LLT, only 16.2% of Colombian participants achieved the LDL-C goal of &lt;&#8201;55&#160;mg/dL [<xref ref-type="bibr" rid="CR55">55</xref>]. Finally, a study of 5,888 patients found a similar pattern in primary and secondary prevention for those at very high CVR. In this study, target achievement also declined from 2016 to 2019, regardless of statin intensity or the addition of non-statin therapies like ezetimibe and PCSK9i [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par45">In the US, a cohort of patients with CAD followed after coronary angiogram demonstrated LDL-C goal achievement rates under the 2016 ESC/EAS guideline of 53.9% at three months, 57.6% at six months, and 53.2% at 12 months. For the stricter 2019 ESC/EAS guideline, the rates were 32.8%, 27.3%, and 32.5% at three, six, and 12 months, respectively, reflecting stability over time for the 2016 threshold and minor fluctuations for the 2019 threshold [<xref ref-type="bibr" rid="CR56">56</xref>]. Similarly, in our cohort, LDL-C target achievement rates under the 2016 ESC/EAS guideline were 44.2% at three months, 45.3% at six months, and 40.6% at 12 months. For the stricter 2019 ESC/EAS guideline, the rates were lower, starting at 30.4% at three months and increasing slightly to 36.5% at six months and 38.6% by 12 months. These results demonstrate the sustained difficulty in achieving LDL-C targets that persists over time, particularly under more stringent guidelines, while showing relatively stable achievement patterns throughout the follow-up period.</p><p id="Par46">However, the number of follow-up measurements performed during that period appears to play a crucial role in achieving LDL-C goals in patients with CAD. In a cohort reported by Waldeyer et al., with a median follow-up of 353 days, 42% had only one LDL-C measurement, while 29% had two and 29% had three, reflecting a relatively balanced distribution across these groups [<xref ref-type="bibr" rid="CR57">57</xref>]. A different pattern emerged in our population, where 60.6% of patients had only one follow-up measurement, 28.1% had two, 9.8% had three, and just 1.4% had four follow-ups in a 12-month period. Despite these variations, a clear trend was observed in both study populations: the proportion of patients achieving LDL-C targets increased progressively with the number of follow-ups, reaching 45.5% with three follow-ups in our population and 44.7% in the previously mentioned study. Moreover, greater reductions in LDL-C levels were observed as follow-up frequency increased. For example, in patients without CVR stratification, more frequent LDL-C monitoring was associated with a reduction of 12.9&#160;mg/dL in men and 13.5&#160;mg/dL in women after six follow-up visits [<xref ref-type="bibr" rid="CR58">58</xref>]. Similarly, in post-ACS patients, those who underwent more frequent follow-up during the first year achieved substantially better LDL-C control at one year compared to those with only a single 12-month visit [<xref ref-type="bibr" rid="CR59">59</xref>]. These findings underscore the importance of regular LDL-C monitoring as a key determinant of goal achievement.</p><p id="Par47">Despite the importance of follow-up frequency in achieving LDL-C targets, adopting frequent monitoring strategies may entail substantial healthcare costs. Even the Canadian Cardiovascular Society&#8217;s conservative approach&#8212;testing every 3&#8211;5 years or annually depending on risk&#8212;would require 3.6&#160;million extra tests and 52.2&#160;million Canadian dollars [<xref ref-type="bibr" rid="CR60">60</xref>]. In contrast, for very high CVR patients such as those in our cohort, the ESC/EAS 2019 guidelines advocate more frequent assessments, which could place an even greater financial burden on healthcare systems [<xref ref-type="bibr" rid="CR3">3</xref>]. Nonetheless, given its value in achieving LDL-C goals, follow-up frequency warrants further investigation and optimization to improve its cost-effectiveness.</p><p id="Par48">LDL-C levels play a crucial role in reducing CVR and improving long-term outcomes in patients with CAD. In a retrospective study of 1,360 patients treated for MI, the average LDL-C level one year after discharge was 72&#8201;&#177;&#8201;23&#160;mg/dL in the total population, a value similar to that observed in our cohort (73.5&#8201;&#177;&#8201;33.8&#160;mg/dL). Among patients who achieved LDL-C goals, the levels were lower in our cohort (44.4&#8201;&#177;&#8201;12.4&#160;mg/dL) compared to the previous study (52&#8201;&#177;&#8201;11&#160;mg/dL); conversely, among those who did not reach targets, LDL-C levels were higher in our cohort (90.3&#8201;&#177;&#8201;30.6&#160;mg/dL vs. 84&#8201;&#177;&#8201;21&#160;mg/dL) [<xref ref-type="bibr" rid="CR61">61</xref>]. While overall LDL-C levels were similar between cohorts, patients who achieved therapeutic targets in our study had a favorable lipid profile.</p><p id="Par49">The low LDL-C goal achievement rates may stem from several factors, with patient adherence being a key one. Research shows that about 50% of patients with chronic illnesses do not take their medications as prescribed [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Common reasons for discontinuation or refusal include fear of side effects, perceived adverse effects, and concerns about statin safety&#8212;factors that likely compromise LLT adherence and LDL-C control [<xref ref-type="bibr" rid="CR41">41</xref>]. In addition, unhealthy lifestyle habits may substantially affect LDL-C control. A multicenter study across 27 countries involving 8,261 patients with CAD found that 19% had a history of smoking, with 55% being persistent smokers. Moreover, 32% were obese, and 41% had no intention to lose weight within six months. Regarding physical activity, 42% did not engage in regular exercise and had no plans to start [<xref ref-type="bibr" rid="CR64">64</xref>]. The low availability and accessibility of statins in upper and lower middle-income countries, as well as in South America, may impact goal attainment and should be carefully considered, given their association with MACE outcomes and increased all-cause mortality [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. Additionally, the COVID-19 pandemic may have worsened this issue in 2021&#8211;2022 by disrupting healthcare services and limiting medication access [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. Finally, factors such as inadequate statin intensity, clinical inertia, and ineffective patient-physician communication may also impact these observations [<xref ref-type="bibr" rid="CR53">53</xref>].</p><p id="Par50">Furthermore, a consistent decline in LDL-C goal achievement has been observed when applying the stricter 55&#160;mg/dL threshold, both in our study and in others. Despite well-established recommendations, meeting the LDL-C goal set by the 2019 ESC/EAS guideline remains challenging with conventional statin therapy, even when combined with ezetimibe. Data from the SWEDEHEART registry, which included over 25,000 recent MI patients, assessed the efficacy of various LLT. A Monte Carlo simulation showed that only 20% of patients on high-intensity statins achieved the LDL-C goal, rising to 28.5% with ezetimibe. Notably, adding PCSK9i in eligible patients increased achievement to approximately 90% [<xref ref-type="bibr" rid="CR69">69</xref>]. Real-world data from the DA VINCI study support these findings, showing that among very high CVR patients, the decline in LDL-C goal achievement from the 2016 to 2019 guidelines was less pronounced in those receiving PCSK9i [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par51">While these results highlight the efficacy of advanced LLT, authors suggest that achieving the 2019 LDL-C target would require widespread use of non-statin therapies, such as PCSK9i, in very high CVR patients. However, it would pose significant financial constraints, particularly for resource-limited healthcare systems [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. This could relate to our findings, where&#8212;despite a gradual increase in PCSK9i prescriptions over the years&#8212;their use remains relatively low compared to statin monotherapy. In fact, the limited availability of these agents in Colombia may further hinder LDL-C goal achievement, reflecting trends reported in previous studies and underscoring the broader challenges of implementing non-statin therapies in low- and middle-income settings.</p></sec><sec id="Sec9"><title>Strengths and limitations</title><p id="Par52">One strength of this study is its multicenter design, involving institutions from various regions of Colombia, and its relatively large sample size, which enhances the generalizability of findings. The 12-month follow-up with multiple measurements allows for a comprehensive assessment of LDL-C goal achievement and LLT use over time. The application of ESC/EAS guidelines ensures comparability with international studies. By analyzing three distinct time periods aligned with successive ESC/EAS guideline updates&#8212;reflecting evolving LDL-C targets, while applying consistent patient selection criteria&#8212;this study captures period effects reflecting changes in real-world clinical practice, while minimizing cohort effects. In a country where research resources are often limited, this study also reflects a significant national effort to establish collaborations and generate local evidence in CVR management. This research provides valuable insight into LLT usage and LDL-C control and may serve as a foundation for future large-scale registries and studies in similar healthcare systems.</p><p id="Par53">However, this study has several limitations. First, the use of a non-probabilistic sampling approach limits the representativeness of the sample. This is an initial analysis based on an interim dataset, as patient recruitment is still ongoing. Additionally, the variables were obtained from medical records, which may contain incomplete or inaccurate information, potentially affecting data reliability. Given our inclusion criteria, there was significant heterogeneity in the number of follow-up visits among patients. The study was also limited to high-complexity centers in Colombia, which may restrict the external validity of the findings, particularly regarding their applicability to primary or secondary care settings and to other regions. Moreover, the limited inclusion of patients from the 2011 ESC/EAS group&#8212;likely due to data traceability issues&#8212;may have reduced the representativeness of that period. Furthermore, LDL-C was measured either directly or estimated using the Friedewald equation, potentially introducing variability in lipid profile assessments, particularly in patients with elevated triglyceride levels. LLT adherence and its potential determinants were not assessed, which may be relevant factors influencing LDL-C goal achievement. Finally, the absence of data from 2020 due to the COVID-19 pandemic limits the assessment of its actual impact on LDL-C control in patients managed under the 2019 ESC/EAS guideline.</p></sec><sec id="Sec10"><title>Conclusions</title><p id="Par54">Despite widespread LLT use, LDL-C goal achievement remains suboptimal, particularly under the more stringent 2019 ESC/EAS guideline. Those findings highlight the ongoing challenge of optimizing lipid control, emphasizing the importance of adherence, follow-up monitoring, and potentially greater use of combination therapies. The observed trend of improved LDL-C reduction with more follow-up assessments suggests that consistent patient monitoring plays a crucial role in treatment success. Future research should explore strategies to enhance adherence and evaluate the impact of emerging LLT in real-world clinical practice.</p></sec><sec id="Sec11" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="12944_2025_2657_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Brayan Daniel Cordoba-Melo and Sebasti&#225;n Seni-Molina contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank Catalina Lopera Carvajal (Fundaci&#243;n Ideas Auna, Medell&#237;n, Colombia), Estefania Vel&#225;squez L&#243;pez (Cl&#237;nica El Rosario, Medell&#237;n, Colombia), Ana Mar&#237;a Vargas Suaza (Fundaci&#243;n Cardioinfantil-Instituto de Cardiolog&#237;a, Bogot&#225;, Colombia), and Nancy Yirlei Olaya (Fundaci&#243;n Valle del Lili, Cali, Colombia) for their valuable contributions to patient recruitment. We also extend our gratitude to all the individuals and institutions involved in the execution of the EDHIPO MARCA Registry, whose collective efforts have been essential to the success of this project.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization was led by B.D.C.-M., S.S.-M., and J.P.A.-I. Methodology was developed by B.D.C.-M., S.S.-M., H.L.-G., J.E.G.-M., A.J.R., and D.I.M. Formal analysis and data curation were conducted by B.D.C.-M., S.S.-M., and J.P.A.-I. Validation was carried out by B.D.C.-M. and S.S.-M. Investigation was performed by B.D.C.-M., S.S.-M., J.P.A.-I., M.R.A., J.F.T.-M., V.Q.Y., L.A.M.C., J.D.C.-C., N.A.-O., A.B., J.P.L.-L., A.H., J.S., C.R.-V., &#193;.H.-E., J.S.H., J.F.V.O., L.V., H.L.-G., A.J.R., D.I.M., and J.E.G.-M. Visualization was conducted by B.D.C.-M., S.S.-M., and J.P.A.-I. Study supervision, project administration, and resource management were overseen by J.E.G.-M., A.J.R., and D.I.M. Funding acquisition was managed by J.E.G.-M. All authors contributed to writing the original draft and to reviewing and editing the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The Centro de Investigaciones Clinicas of Fundaci&#243;n Valle del Lili received an unrestricted grant (CS_00792) from Sanofi to support the development of the EDHIPO MARCA Registry.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par55">The study is conducted in accordance with the principles outlined in the Declaration of Helsinki [<xref ref-type="bibr" rid="CR72">72</xref>]. The study protocol was approved by the ethics committees of each participating center and was classified as minimal risk in accordance with Resolution 8430 of 1993 from the Colombian Ministry of Health. Informed consent was not required due to the study&#8217;s retrospective design and minimal risk classification. The study protocol was approved by the Comit&#233; de &#201;tica en Investigaci&#243;n Biom&#233;dica of Fundaci&#243;n Valle del Lili (approval number: 2023.2124) and was classified as minimal risk under Resolution 8430 of 1993 from the Colombian Ministry of Health. Additionally, the protocol was submitted to and approved by the ethics committees of all participating centers. Informed consent was not required due to the retrospective design of the study and its classification as minimal risk.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par56">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par57">Two authors of this study, S.L. and C.S., are Sanofi employees and may hold shares and/or stock options in the company; however, their participation in this research does not represent the interests of their institution. The funding organization had no role in the study design, data collection, analysis, interpretation, or manuscript preparation. The remaining authors declare that they have no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>ASCVD</term><def><p id="Par58">Atherosclerotic Cardiovascular Disease</p></def></def-item><def-item><term>CAD</term><def><p id="Par59">Coronary Artery Disease</p></def></def-item><def-item><term>CI</term><def><p id="Par60">Confidence Interval</p></def></def-item><def-item><term>CKD</term><def><p id="Par61">Chronic Kidney Disease</p></def></def-item><def-item><term>CRF</term><def><p id="Par62">Case Report Form</p></def></def-item><def-item><term>CVD</term><def><p id="Par63">Cardiovascular Disease</p></def></def-item><def-item><term>CVR</term><def><p id="Par64">Cardiovascular Risk</p></def></def-item><def-item><term>DALY</term><def><p id="Par65">Disability-Adjusted Life Year</p></def></def-item><def-item><term>DM</term><def><p id="Par66">Diabetes Mellitus</p></def></def-item><def-item><term>EDHIPO MARCA</term><def><p id="Par67">Evaluaci&#243;n De adherencia a la terapia HIPOlipemiante en pacientes de Muy Alto Riesgo Cardiovascular</p></def></def-item><def-item><term>ESC/EAS</term><def><p id="Par68">European Society of Cardiology / European Atherosclerosis Society</p></def></def-item><def-item><term>HF</term><def><p id="Par69">Heart Failure</p></def></def-item><def-item><term>HTN</term><def><p id="Par70">Hypertension</p></def></def-item><def-item><term>IQR</term><def><p id="Par71">Interquartile Range</p></def></def-item><def-item><term>LDL-C</term><def><p id="Par72">Low-Density Lipoprotein Cholesterol</p></def></def-item><def-item><term>LLT</term><def><p id="Par73">Lipid-Lowering Therapy</p></def></def-item><def-item><term>LVEF</term><def><p id="Par74">Left Ventricular Ejection Fraction</p></def></def-item><def-item><term>MI</term><def><p id="Par75">Myocardial Infarction</p></def></def-item><def-item><term>NSTEMI</term><def><p id="Par76">Non-ST Elevation Myocardial Infarction</p></def></def-item><def-item><term>PCSK9i</term><def><p id="Par77">Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors</p></def></def-item><def-item><term>REDCap</term><def><p id="Par78">Research Electronic Data Capture</p></def></def-item><def-item><term>STEMI</term><def><p id="Par79">ST Elevation Myocardial Infarction</p></def></def-item><def-item><term>US</term><def><p id="Par80">United States</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Magnussen</surname><given-names>CG</given-names></name><name name-style="western"><surname>Xi</surname><given-names>B</given-names></name></person-group><article-title>Global, regional, and National burden of cardiovascular diseases in youths and young adults aged 15&#8211;39 years in 204 countries/territories, 1990&#8211;2019: a systematic analysis of global burden of disease study 2019</article-title><source>BMC Med</source><year>2023</year><volume>21</volume><issue>1</issue><fpage>222</fpage><pub-id pub-id-type="pmid">37365627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-023-02925-4</pub-id><pub-id pub-id-type="pmcid">PMC10294522</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sun J, Qiao Y, Zhao M, Magnussen CG, Xi B. Global, regional, and National burden of cardiovascular diseases in youths and young adults aged 15&#8211;39 years in 204 countries/territories, 1990&#8211;2019: a systematic analysis of global burden of disease study 2019. BMC Med. 2023;21(1):222.<pub-id pub-id-type="pmid">37365627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12916-023-02925-4</pub-id><pub-id pub-id-type="pmcid">PMC10294522</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>GA</given-names></name><name name-style="western"><surname>Mensah</surname><given-names>GA</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>CO</given-names></name><name name-style="western"><surname>Addolorato</surname><given-names>G</given-names></name><name name-style="western"><surname>Ammirati</surname><given-names>E</given-names></name><name name-style="western"><surname>Baddour</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Global burden of cardiovascular diseases and risk factors, 1990&#8211;2019: update from the GBD 2019 study</article-title><source>J Am Coll Cardiol</source><year>2020</year><volume>76</volume><issue>25</issue><fpage>2982</fpage><lpage>3021</lpage><pub-id pub-id-type="pmid">33309175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2020.11.010</pub-id><pub-id pub-id-type="pmcid">PMC7755038</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990&#8211;2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982&#8211;3021.<pub-id pub-id-type="pmid">33309175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2020.11.010</pub-id><pub-id pub-id-type="pmcid">PMC7755038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mach</surname><given-names>F</given-names></name><name name-style="western"><surname>Baigent</surname><given-names>C</given-names></name><name name-style="western"><surname>Catapano</surname><given-names>AL</given-names></name><name name-style="western"><surname>Koskinas</surname><given-names>KC</given-names></name><name name-style="western"><surname>Casula</surname><given-names>M</given-names></name><name name-style="western"><surname>Badimon</surname><given-names>L</given-names></name><etal/></person-group><article-title>2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS)</article-title><source>Eur Heart J</source><year>2020</year><volume>41</volume><issue>1</issue><fpage>111</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">31504418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehz455</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). Eur Heart J. 2020;41(1):111&#8211;88.<pub-id pub-id-type="pmid">31504418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehz455</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mozaffarian</surname><given-names>D</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Go</surname><given-names>AS</given-names></name><name name-style="western"><surname>Arnett</surname><given-names>DK</given-names></name><name name-style="western"><surname>Blaha</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cushman</surname><given-names>M</given-names></name><etal/></person-group><source>Heart Disease Stroke Statistics&#8212;2016 Update Circulation</source><year>2016</year><volume>133</volume><issue>4</issue><fpage>e38</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">26673558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000000350</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart Disease Stroke Statistics&#8212;2016 Update Circulation. 2016;133(4):e38&#8211;360.<pub-id pub-id-type="pmid">26673558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIR.0000000000000350</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bauersachs</surname><given-names>R</given-names></name><name name-style="western"><surname>Zeymer</surname><given-names>U</given-names></name><name name-style="western"><surname>Bri&#232;re</surname><given-names>JB</given-names></name><name name-style="western"><surname>Marre</surname><given-names>C</given-names></name><name name-style="western"><surname>Bowrin</surname><given-names>K</given-names></name><name name-style="western"><surname>Huelsebeck</surname><given-names>M</given-names></name></person-group><article-title>Burden of coronary artery disease and peripheral artery disease: A literature review</article-title><source>Cardiovasc Ther</source><year>2019</year><volume>2019</volume><issue>1</issue><fpage>8295054</fpage><pub-id pub-id-type="pmid">32099582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2019/8295054</pub-id><pub-id pub-id-type="pmcid">PMC7024142</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Bauersachs R, Zeymer U, Bri&#232;re JB, Marre C, Bowrin K, Huelsebeck M. Burden of coronary artery disease and peripheral artery disease: A literature review. Cardiovasc Ther. 2019;2019(1):8295054.<pub-id pub-id-type="pmid">32099582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2019/8295054</pub-id><pub-id pub-id-type="pmcid">PMC7024142</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ralapanawa</surname><given-names>U</given-names></name><name name-style="western"><surname>Sivakanesan</surname><given-names>R</given-names></name></person-group><article-title>Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: A narrative review</article-title><source>J Epidemiol Glob Health</source><year>2021</year><volume>11</volume><issue>2</issue><fpage>169</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">33605111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2991/jegh.k.201217.001</pub-id><pub-id pub-id-type="pmcid">PMC8242111</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Ralapanawa U, Sivakanesan R. Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: A narrative review. J Epidemiol Glob Health. 2021;11(2):169&#8211;77.<pub-id pub-id-type="pmid">33605111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2991/jegh.k.201217.001</pub-id><pub-id pub-id-type="pmcid">PMC8242111</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roth</surname><given-names>GA</given-names></name><name name-style="western"><surname>Mensah</surname><given-names>GA</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>CO</given-names></name><name name-style="western"><surname>Addolorato</surname><given-names>G</given-names></name><name name-style="western"><surname>Ammirati</surname><given-names>E</given-names></name><name name-style="western"><surname>Baddour</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Global burden of cardiovascular diseases and risk factors, 1990&#8211;2019</article-title><source>J Am Coll Cardiol</source><year>2020</year><volume>76</volume><issue>25</issue><fpage>2982</fpage><lpage>3021</lpage><pub-id pub-id-type="pmid">33309175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2020.11.010</pub-id><pub-id pub-id-type="pmcid">PMC7755038</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990&#8211;2019. J Am Coll Cardiol. 2020;76(25):2982&#8211;3021.<pub-id pub-id-type="pmid">33309175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2020.11.010</pub-id><pub-id pub-id-type="pmcid">PMC7755038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">CVD-A-Costly-Burden. -for-America-Projections-Through-2035.pdf [Internet]. [cited 2025 Feb 10]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.heart.org/-/media/Files/About-Us/Policy-Research/Fact-Sheets/Public-Health-Advocacy-and-Research/CVD-A-Costly-Burden-for-America-Projections-Through-2035.pdf">https://www.heart.org/-/media/Files/About-Us/Policy-Research/Fact-Sheets/Public-Health-Advocacy-and-Research/CVD-A-Costly-Burden-for-America-Projections-Through-2035.pdf</ext-link></mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shakya</surname><given-names>S</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>A</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>S</given-names></name><name name-style="western"><surname>Randall</surname><given-names>S</given-names></name><name name-style="western"><surname>Mnatzaganian</surname><given-names>G</given-names></name><name name-style="western"><surname>Brown</surname><given-names>H</given-names></name><etal/></person-group><article-title>Global comparison of the economic costs of coronary heart disease: a systematic review and meta-analysis</article-title><source>BMJ Open</source><year>2025</year><volume>15</volume><issue>1</issue><fpage>e084917</fpage><pub-id pub-id-type="pmid">39842921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2024-084917</pub-id><pub-id pub-id-type="pmcid">PMC11784380</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Shakya S, Shrestha A, Robinson S, Randall S, Mnatzaganian G, Brown H, et al. Global comparison of the economic costs of coronary heart disease: a systematic review and meta-analysis. BMJ Open. 2025;15(1):e084917.<pub-id pub-id-type="pmid">39842921</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2024-084917</pub-id><pub-id pub-id-type="pmcid">PMC11784380</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Z</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name></person-group><article-title>Dyslipidemia and cardiovascular disease: current knowledge, existing challenges, and new opportunities for management strategies</article-title><source>J Clin Med</source><year>2023</year><volume>12</volume><issue>1</issue><fpage>363</fpage><pub-id pub-id-type="pmid">36615163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12010363</pub-id><pub-id pub-id-type="pmcid">PMC9820834</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Du Z, Qin Y. Dyslipidemia and cardiovascular disease: current knowledge, existing challenges, and new opportunities for management strategies. J Clin Med. 2023;12(1):363.<pub-id pub-id-type="pmid">36615163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12010363</pub-id><pub-id pub-id-type="pmcid">PMC9820834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kattoor</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Kanuri</surname><given-names>SH</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>JL</given-names></name></person-group><article-title>Role of Ox-LDL and LOX-1 in atherogenesis</article-title><source>Curr Med Chem</source><year>2019</year><volume>26</volume><issue>9</issue><fpage>1693</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">29737246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929867325666180508100950</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Kattoor AJ, Kanuri SH, Mehta JL. Role of Ox-LDL and LOX-1 in atherogenesis. Curr Med Chem. 2019;26(9):1693&#8211;700.<pub-id pub-id-type="pmid">29737246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0929867325666180508100950</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ference</surname><given-names>BA</given-names></name><name name-style="western"><surname>Ginsberg</surname><given-names>HN</given-names></name><name name-style="western"><surname>Graham</surname><given-names>I</given-names></name><name name-style="western"><surname>Ray</surname><given-names>KK</given-names></name><name name-style="western"><surname>Packard</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Bruckert</surname><given-names>E</given-names></name><etal/></person-group><article-title>Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><issue>32</issue><fpage>2459</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">28444290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehx144</pub-id><pub-id pub-id-type="pmcid">PMC5837225</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38(32):2459&#8211;72.<pub-id pub-id-type="pmid">28444290</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehx144</pub-id><pub-id pub-id-type="pmcid">PMC5837225</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Zahrani</surname><given-names>J</given-names></name><name name-style="western"><surname>Shubair</surname><given-names>MM</given-names></name><name name-style="western"><surname>Al-Ghamdi</surname><given-names>S</given-names></name><name name-style="western"><surname>Alrasheed</surname><given-names>AA</given-names></name><name name-style="western"><surname>Alduraywish</surname><given-names>AA</given-names></name><name name-style="western"><surname>Alreshidi</surname><given-names>FS</given-names></name><etal/></person-group><article-title>The prevalence of hypercholesterolemia and associated risk factors in Al-Kharj population, Saudi arabia: a cross-sectional survey</article-title><source>BMC Cardiovasc Disord</source><year>2021</year><volume>21</volume><issue>1</issue><fpage>22</fpage><pub-id pub-id-type="pmid">33413091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12872-020-01825-2</pub-id><pub-id pub-id-type="pmcid">PMC7792200</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Al-Zahrani J, Shubair MM, Al-Ghamdi S, Alrasheed AA, Alduraywish AA, Alreshidi FS, et al. The prevalence of hypercholesterolemia and associated risk factors in Al-Kharj population, Saudi arabia: a cross-sectional survey. BMC Cardiovasc Disord. 2021;21(1):22.<pub-id pub-id-type="pmid">33413091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12872-020-01825-2</pub-id><pub-id pub-id-type="pmcid">PMC7792200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackinnon</surname><given-names>ES</given-names></name><name name-style="western"><surname>Leiter</surname><given-names>LA</given-names></name><name name-style="western"><surname>Wani</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Burke</surname><given-names>N</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>E</given-names></name><name name-style="western"><surname>Witges</surname><given-names>K</given-names></name><etal/></person-group><article-title>Real-World risk of recurrent cardiovascular events in atherosclerotic cardiovascular disease patients with LDL-C above Guideline-Recommended threshold: A retrospective observational study</article-title><source>Cardiol Ther</source><year>2024</year><volume>13</volume><issue>1</issue><fpage>205</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">38285331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40119-024-00349-6</pub-id><pub-id pub-id-type="pmcid">PMC10899549</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Mackinnon ES, Leiter LA, Wani RJ, Burke N, Shaw E, Witges K, et al. Real-World risk of recurrent cardiovascular events in atherosclerotic cardiovascular disease patients with LDL-C above Guideline-Recommended threshold: A retrospective observational study. Cardiol Ther. 2024;13(1):205&#8211;20.<pub-id pub-id-type="pmid">38285331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40119-024-00349-6</pub-id><pub-id pub-id-type="pmcid">PMC10899549</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><collab>Cholesterol Treatment Trialists&#8217; (CTT)</collab><name name-style="western"><surname>Collaboration, Baigent</surname><given-names>C</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>L</given-names></name><name name-style="western"><surname>Emberson</surname><given-names>J</given-names></name><name name-style="western"><surname>Holland</surname><given-names>LE</given-names></name><name name-style="western"><surname>Reith</surname><given-names>C</given-names></name><etal/></person-group><article-title>Efficacy and safety of more intensive Lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials</article-title><source>Lancet Lond Engl</source><year>2010</year><volume>376</volume><issue>9753</issue><fpage>1670</fpage><lpage>81</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(10)61350-5</pub-id><pub-id pub-id-type="pmcid">PMC2988224</pub-id><pub-id pub-id-type="pmid">21067804</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Cholesterol Treatment Trialists&#8217; (CTT), Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive Lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet Lond Engl. 2010;376(9753):1670&#8211;81.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(10)61350-5</pub-id><pub-id pub-id-type="pmcid">PMC2988224</pub-id><pub-id pub-id-type="pmid">21067804</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munkhaugen</surname><given-names>J</given-names></name><name name-style="western"><surname>Sverre</surname><given-names>E</given-names></name><name name-style="western"><surname>Otterstad</surname><given-names>JE</given-names></name><name name-style="western"><surname>Peersen</surname><given-names>K</given-names></name><name name-style="western"><surname>Gjertsen</surname><given-names>E</given-names></name><name name-style="western"><surname>Perk</surname><given-names>J</given-names></name><etal/></person-group><article-title>Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients</article-title><source>Eur J Prev Cardiol</source><year>2017</year><volume>24</volume><issue>9</issue><fpage>981</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">28196429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2047487317693134</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Munkhaugen J, Sverre E, Otterstad JE, Peersen K, Gjertsen E, Perk J, et al. Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. Eur J Prev Cardiol. 2017;24(9):981&#8211;9.<pub-id pub-id-type="pmid">28196429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2047487317693134</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Ji</surname><given-names>F</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Factors associated with unattained LDL-cholesterol goals in Chinese patients with acute coronary syndrome one year after percutaneous coronary intervention</article-title><source>Med (Baltim)</source><year>2017</year><volume>96</volume><issue>1</issue><fpage>e5469</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000005469</pub-id><pub-id pub-id-type="pmcid">PMC5228648</pub-id><pub-id pub-id-type="pmid">28072688</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Zhang W, Ji F, Yu X, Wang X. Factors associated with unattained LDL-cholesterol goals in Chinese patients with acute coronary syndrome one year after percutaneous coronary intervention. Med (Baltim). 2017;96(1):e5469.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000005469</pub-id><pub-id pub-id-type="pmcid">PMC5228648</pub-id><pub-id pub-id-type="pmid">28072688</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>NP</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>H</given-names></name><name name-style="western"><surname>Lydon</surname><given-names>E</given-names></name><name name-style="western"><surname>Chiswell</surname><given-names>K</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Lampron</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Real-world exploration of LDL-cholesterol management in patients with atherosclerotic cardiovascular disease</article-title><source>Am Heart J</source><year>2025</year><volume>279</volume><fpage>50</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">39423990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ahj.2024.10.009</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Shah NP, Mulder H, Lydon E, Chiswell K, Hu X, Lampron Z, et al. Real-world exploration of LDL-cholesterol management in patients with atherosclerotic cardiovascular disease. Am Heart J. 2025;279:50&#8211;8.<pub-id pub-id-type="pmid">39423990</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ahj.2024.10.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merch&#225;n Villamizar</surname><given-names>A</given-names></name><name name-style="western"><surname>Garc&#237;a Pe&#241;a</surname><given-names>&#193;A</given-names></name><name name-style="western"><surname>Isaza Restrepo</surname><given-names>D</given-names></name><name name-style="western"><surname>Isaza</surname><given-names>N</given-names></name><name name-style="western"><surname>Reynales</surname><given-names>H</given-names></name></person-group><article-title>Logro de Las Metas de colesterol LDL En Pacientes Con Enfermedad coronaria Ateroscler&#243;tica Establecida</article-title><source>Rev Colomb Cardiol</source><year>2020</year><volume>27</volume><issue>6</issue><fpage>508</fpage><lpage>13</lpage></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Merch&#225;n Villamizar A, Garc&#237;a Pe&#241;a &#193;A, Isaza Restrepo D, Isaza N, Reynales H. Logro de Las Metas de colesterol LDL En Pacientes Con Enfermedad coronaria Ateroscler&#243;tica Establecida. Rev Colomb Cardiol. 2020;27(6):508&#8211;13.</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Pinto-Gonz&#225;lez G, Uribe-Velez NA, Quir&#243;s-G&#243;mez OI. Factores asociados al logro de metas en pacientes con dislipidemia en atenci&#243;n primaria. Iatreia [Internet]. 2025 [cited 2025 Feb 10];38(1). Available from: <ext-link ext-link-type="uri" xlink:href="https://revistas.udea.edu.co/index.php/iatreia/article/view/349827">https://revistas.udea.edu.co/index.php/iatreia/article/view/349827</ext-link></mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diaztagle</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Chaves</surname><given-names>WG</given-names></name><name name-style="western"><surname>Sprockel</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Sastoque</surname><given-names>JA</given-names></name><name name-style="western"><surname>Nieto</surname><given-names>JA</given-names></name><name name-style="western"><surname>Barreto</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Cumplimiento de Metas de l&#237;pidos En Pacientes de prevenci&#243;n secundaria hospitalizados Por medicina Interna</article-title><source>Acta Med Colomb</source><year>2013</year><volume>38</volume><issue>2</issue><fpage>54</fpage><lpage>60</lpage></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Diaztagle JJ, Chaves WG, Sprockel JJ, Sastoque JA, Nieto JA, Barreto GA, et al. Cumplimiento de Metas de l&#237;pidos En Pacientes de prevenci&#243;n secundaria hospitalizados Por medicina Interna. Acta Med Colomb. 2013;38(2):54&#8211;60.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Machado-Alba JE, Machado-Duque ME, Echeverri MCY, Manrique-Casta&#241;o S, Tob&#243;n LM. Tratamiento hipolipemiante y su efectividad en pacientes de cuatro ciudades colombianas, 2012&#8211;2013. Acta M&#233;dica Colomb [Internet]. 2016 [cited 2025 Feb 10];41(3). Available from: <ext-link ext-link-type="uri" xlink:href="https://www.actamedicacolombiana.com/ojs/index.php/actamed/article/view/727">https://www.actamedicacolombiana.com/ojs/index.php/actamed/article/view/727</ext-link></mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yusuf</surname><given-names>S</given-names></name><name name-style="western"><surname>Islam</surname><given-names>S</given-names></name><name name-style="western"><surname>Chow</surname><given-names>CK</given-names></name><name name-style="western"><surname>Rangarajan</surname><given-names>S</given-names></name><name name-style="western"><surname>Dagenais</surname><given-names>G</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>R</given-names></name><etal/></person-group><article-title>Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey</article-title><source>Lancet Lond Engl</source><year>2011</year><volume>378</volume><issue>9798</issue><fpage>1231</fpage><lpage>43</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(11)61215-4</pub-id><pub-id pub-id-type="pmid">21872920</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet Lond Engl. 2011;378(9798):1231&#8211;43.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(11)61215-4</pub-id><pub-id pub-id-type="pmid">21872920</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><collab>European Association for Cardiovascular Prevention &amp;</collab><name name-style="western"><surname>Rehabilitation, Reiner</surname><given-names>Z</given-names></name><name name-style="western"><surname>Catapano</surname><given-names>AL</given-names></name><name name-style="western"><surname>De Backer</surname><given-names>G</given-names></name><name name-style="western"><surname>Graham</surname><given-names>I</given-names></name><name name-style="western"><surname>Taskinen</surname><given-names>MR</given-names></name><etal/></person-group><article-title>ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS)</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><issue>14</issue><fpage>1769</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">21712404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehr158</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">European Association for Cardiovascular Prevention &amp;, Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and the European atherosclerosis society (EAS). Eur Heart J. 2011;32(14):1769&#8211;818.<pub-id pub-id-type="pmid">21712404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehr158</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catapano</surname><given-names>AL</given-names></name><name name-style="western"><surname>Graham</surname><given-names>I</given-names></name><name name-style="western"><surname>De Backer</surname><given-names>G</given-names></name><name name-style="western"><surname>Wiklund</surname><given-names>O</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Drexel</surname><given-names>H</given-names></name><etal/></person-group><article-title>2016 ESC/EAS guidelines for the management of dyslipidaemias</article-title><source>Eur Heart J</source><year>2016</year><volume>37</volume><issue>39</issue><fpage>2999</fpage><lpage>3058</lpage><pub-id pub-id-type="pmid">27567407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehw272</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999&#8211;3058.<pub-id pub-id-type="pmid">27567407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehw272</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health &#8211; Eur [Internet]. 2023 Jun 1 [cited 2025 Feb 10];29. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00043-1/fulltext">https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00043-1/fulltext</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lanepe.2023.100624</pub-id><pub-id pub-id-type="pmcid">PMC10119631</pub-id><pub-id pub-id-type="pmid">37090089</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Visseren</surname><given-names>FLJ</given-names></name><name name-style="western"><surname>Mach</surname><given-names>F</given-names></name><name name-style="western"><surname>Smulders</surname><given-names>YM</given-names></name><name name-style="western"><surname>Carballo</surname><given-names>D</given-names></name><name name-style="western"><surname>Koskinas</surname><given-names>KC</given-names></name><name name-style="western"><surname>B&#228;ck</surname><given-names>M</given-names></name><etal/></person-group><article-title>2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European society of cardiology and 12 medical societies with the special contribution of the European association of preventive cardiology (EAPC)</article-title><source>Eur Heart J</source><year>2021</year><volume>42</volume><issue>34</issue><fpage>3227</fpage><lpage>337</lpage></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, B&#228;ck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European society of cardiology and 12 medical societies with the special contribution of the European association of preventive cardiology (EAPC). Eur Heart J. 2021;42(34):3227&#8211;337.34458905
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedewald</surname><given-names>WT</given-names></name><name name-style="western"><surname>Levy</surname><given-names>RI</given-names></name><name name-style="western"><surname>Fredrickson</surname><given-names>DS</given-names></name></person-group><article-title>Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge</article-title><source>Clin Chem</source><year>1972</year><volume>18</volume><issue>6</issue><fpage>499</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">4337382</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499&#8211;502.<pub-id pub-id-type="pmid">4337382</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Head</surname><given-names>T</given-names></name><name name-style="western"><surname>Daunert</surname><given-names>S</given-names></name><name name-style="western"><surname>Goldschmidt-Clermont</surname><given-names>PJ</given-names></name></person-group><article-title>The aging risk and atherosclerosis: A fresh look at arterial homeostasis</article-title><source>Front Genet</source><year>2017</year><volume>8</volume><fpage>216</fpage><pub-id pub-id-type="pmid">29312440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2017.00216</pub-id><pub-id pub-id-type="pmcid">PMC5735066</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Head T, Daunert S, Goldschmidt-Clermont PJ. The aging risk and atherosclerosis: A fresh look at arterial homeostasis. Front Genet. 2017;8:216.<pub-id pub-id-type="pmid">29312440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2017.00216</pub-id><pub-id pub-id-type="pmcid">PMC5735066</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Luca</surname><given-names>L</given-names></name><name name-style="western"><surname>Arca</surname><given-names>M</given-names></name><name name-style="western"><surname>Temporelli</surname><given-names>PL</given-names></name><name name-style="western"><surname>Meessen</surname><given-names>J</given-names></name><name name-style="western"><surname>Riccio</surname><given-names>C</given-names></name><name name-style="western"><surname>Bonomo</surname><given-names>P</given-names></name><etal/></person-group><article-title>Current lipid Lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: insights from the START registry</article-title><source>Int J Cardiol</source><year>2020</year><volume>316</volume><fpage>229</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">32470532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcard.2020.05.055</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">De Luca L, Arca M, Temporelli PL, Meessen J, Riccio C, Bonomo P, et al. Current lipid Lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: insights from the START registry. Int J Cardiol. 2020;316:229&#8211;35.<pub-id pub-id-type="pmid">32470532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcard.2020.05.055</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ray</surname><given-names>KK</given-names></name><name name-style="western"><surname>Molemans</surname><given-names>B</given-names></name><name name-style="western"><surname>Schoonen</surname><given-names>WM</given-names></name><name name-style="western"><surname>Giovas</surname><given-names>P</given-names></name><name name-style="western"><surname>Bray</surname><given-names>S</given-names></name><name name-style="western"><surname>Kiru</surname><given-names>G</given-names></name><etal/></person-group><article-title>EU-Wide Cross-Sectional observational study of Lipid-Modifying therapy use in secondary and primary care: the DA VINCI study</article-title><source>Eur J Prev Cardiol</source><year>2021</year><volume>28</volume><issue>11</issue><fpage>1279</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">33580789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurjpc/zwaa047</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-Wide Cross-Sectional observational study of Lipid-Modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279&#8211;89.<pub-id pub-id-type="pmid">33580789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurjpc/zwaa047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HL</given-names></name></person-group><article-title>Differences in risk factors for coronary atherosclerosis according to sex</article-title><source>J Lipid Atheroscler</source><year>2024</year><volume>13</volume><issue>2</issue><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">38826179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12997/jla.2024.13.2.97</pub-id><pub-id pub-id-type="pmcid">PMC11140242</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kim HL. Differences in risk factors for coronary atherosclerosis according to sex. J Lipid Atheroscler. 2024;13(2):97&#8211;110.<pub-id pub-id-type="pmid">38826179</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12997/jla.2024.13.2.97</pub-id><pub-id pub-id-type="pmcid">PMC11140242</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Lopez</surname><given-names>JP</given-names></name><name name-style="western"><surname>Toro</surname><given-names>MRD</given-names></name><name name-style="western"><surname>Martinez-Bello</surname><given-names>D</given-names></name><name name-style="western"><surname>Garcia-Pe&#241;a</surname><given-names>&#193;A</given-names></name><name name-style="western"><surname>O&#8217;Donovan</surname><given-names>G</given-names></name><name name-style="western"><surname>Perez-Mayorga</surname><given-names>M</given-names></name><etal/></person-group><article-title>Sex differences in cardiovascular disease risk factor prevalence, morbidity, and mortality in colombia: findings from the prospective urban rural epidemiology (PURE) study</article-title><source>Glob Heart</source><year>2024</year><volume>19</volume><issue>1</issue><fpage>10</fpage><pub-id pub-id-type="pmid">38273994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5334/gh.1289</pub-id><pub-id pub-id-type="pmcid">PMC10809858</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Lopez-Lopez JP, Toro MRD, Martinez-Bello D, Garcia-Pe&#241;a &#193;A, O&#8217;Donovan G, Perez-Mayorga M, et al. Sex differences in cardiovascular disease risk factor prevalence, morbidity, and mortality in colombia: findings from the prospective urban rural epidemiology (PURE) study. Glob Heart. 2024;19(1):10.<pub-id pub-id-type="pmid">38273994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5334/gh.1289</pub-id><pub-id pub-id-type="pmcid">PMC10809858</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sowers</surname><given-names>JR</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>M</given-names></name><name name-style="western"><surname>Frohlich</surname><given-names>ED</given-names></name></person-group><article-title>Diabetes, hypertension, and cardiovascular disease: an update</article-title><source>Hypertens Dallas Tex 1979</source><year>2001</year><volume>37</volume><issue>4</issue><fpage>1053</fpage><lpage>9</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.hyp.37.4.1053</pub-id><pub-id pub-id-type="pmid">11304502</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertens Dallas Tex 1979. 2001;37(4):1053&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.hyp.37.4.1053</pub-id><pub-id pub-id-type="pmid">11304502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><collab>Global Cardiovascular Risk Consortium</collab><name name-style="western"><surname>Magnussen</surname><given-names>C</given-names></name><name name-style="western"><surname>Ojeda</surname><given-names>FM</given-names></name><name name-style="western"><surname>Leong</surname><given-names>DP</given-names></name><name name-style="western"><surname>Alegre-Diaz</surname><given-names>J</given-names></name><name name-style="western"><surname>Amouyel</surname><given-names>P</given-names></name><etal/></person-group><article-title>Global effect of modifiable risk factors on cardiovascular disease and mortality</article-title><source>N Engl J Med</source><year>2023</year><volume>389</volume><issue>14</issue><fpage>1273</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">37632466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2206916</pub-id><pub-id pub-id-type="pmcid">PMC10589462</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Global Cardiovascular Risk Consortium, Magnussen C, Ojeda FM, Leong DP, Alegre-Diaz J, Amouyel P, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389(14):1273&#8211;85.<pub-id pub-id-type="pmid">37632466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2206916</pub-id><pub-id pub-id-type="pmcid">PMC10589462</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calabr&#242;</surname><given-names>P</given-names></name><name name-style="western"><surname>Spaccarotella</surname><given-names>C</given-names></name><name name-style="western"><surname>Cesaro</surname><given-names>A</given-names></name><name name-style="western"><surname>And&#242;</surname><given-names>G</given-names></name><name name-style="western"><surname>Piccolo</surname><given-names>R</given-names></name><name name-style="western"><surname>De Rosa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in italy: an expert opinion paper of interventional cardiology working group of Italian society of cardiology</article-title><source>J Cardiovasc Med</source><year>2023</year><volume>24</volume><issue>Supplement 1</issue><fpage>e86</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2459/JCM.0000000000001440</pub-id><pub-id pub-id-type="pmid">37052225</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Calabr&#242; P, Spaccarotella C, Cesaro A, And&#242; G, Piccolo R, De Rosa S, et al. Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in italy: an expert opinion paper of interventional cardiology working group of Italian society of cardiology. J Cardiovasc Med. 2023;24(Supplement 1):e86.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2459/JCM.0000000000001440</pub-id><pub-id pub-id-type="pmid">37052225</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grundy</surname><given-names>SM</given-names></name><name name-style="western"><surname>Balady</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Criqui</surname><given-names>MH</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>G</given-names></name><name name-style="western"><surname>Greenland</surname><given-names>P</given-names></name><name name-style="western"><surname>Hiratzka</surname><given-names>LF</given-names></name><etal/></person-group><article-title>When to start Cholesterol-Lowering therapy in patients with coronary heart disease</article-title><source>Circulation</source><year>1997</year><volume>95</volume><issue>6</issue><fpage>1683</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9118557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.95.6.1683</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. When to start Cholesterol-Lowering therapy in patients with coronary heart disease. Circulation. 1997;95(6):1683&#8211;5.<pub-id pub-id-type="pmid">9118557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.95.6.1683</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khatib</surname><given-names>R</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Glowacki</surname><given-names>N</given-names></name><name name-style="western"><surname>McGuiness</surname><given-names>CB</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><name name-style="western"><surname>Wade</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Lipid-Lowering therapy utilization and dosage among patients with acute coronary syndrome events: A retrospective cohort from 12 community hospitals</article-title><source>Clin Epidemiol</source><year>2023</year><volume>15</volume><fpage>547</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">37168051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CLEP.S400903</pub-id><pub-id pub-id-type="pmcid">PMC10166091</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Khatib R, Yeh EJ, Glowacki N, McGuiness CB, Xie H, Wade RL, et al. Lipid-Lowering therapy utilization and dosage among patients with acute coronary syndrome events: A retrospective cohort from 12 community hospitals. Clin Epidemiol. 2023;15:547&#8211;57.<pub-id pub-id-type="pmid">37168051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CLEP.S400903</pub-id><pub-id pub-id-type="pmcid">PMC10166091</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazhar</surname><given-names>F</given-names></name><name name-style="western"><surname>Hjemdahl</surname><given-names>P</given-names></name><name name-style="western"><surname>Clase</surname><given-names>CM</given-names></name><name name-style="western"><surname>Johnell</surname><given-names>K</given-names></name><name name-style="western"><surname>Jernberg</surname><given-names>T</given-names></name><name name-style="western"><surname>Carrero</surname><given-names>JJ</given-names></name></person-group><article-title>Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease</article-title><source>Am Heart J</source><year>2022</year><volume>251</volume><fpage>78</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">35654163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ahj.2022.05.021</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Mazhar F, Hjemdahl P, Clase CM, Johnell K, Jernberg T, Carrero JJ. Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease. Am Heart J. 2022;251:78&#8211;90.<pub-id pub-id-type="pmid">35654163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ahj.2022.05.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaviria-Mendoza</surname><given-names>A</given-names></name><name name-style="western"><surname>Machado-Duque</surname><given-names>ME</given-names></name><name name-style="western"><surname>Machado-Alba</surname><given-names>JE</given-names></name></person-group><article-title>Lipid-lowering drug prescriptions in a group of Colombian patients</article-title><source>Biom&#233;dica</source><year>2019</year><volume>39</volume><issue>4</issue><fpage>759</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">31860186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7705/biomedica.4801</pub-id><pub-id pub-id-type="pmcid">PMC7363356</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Gaviria-Mendoza A, Machado-Duque ME, Machado-Alba JE. Lipid-lowering drug prescriptions in a group of Colombian patients. Biom&#233;dica. 2019;39(4):759&#8211;68.<pub-id pub-id-type="pmid">31860186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7705/biomedica.4801</pub-id><pub-id pub-id-type="pmcid">PMC7363356</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradley</surname><given-names>CK</given-names></name><name name-style="western"><surname>Wang</surname><given-names>TY</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>JG</given-names></name><name name-style="western"><surname>Roger</surname><given-names>VL</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Patient-Reported reasons for declining or discontinuing Statin therapy: insights from the PALM registry</article-title><source>J Am Heart Assoc Cardiovasc Cerebrovasc Dis</source><year>2019</year><volume>8</volume><issue>7</issue><fpage>e011765</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.118.011765</pub-id><pub-id pub-id-type="pmcid">PMC6509731</pub-id><pub-id pub-id-type="pmid">30913959</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Bradley CK, Wang TY, Li S, Robinson JG, Roger VL, Goldberg AC, et al. Patient-Reported reasons for declining or discontinuing Statin therapy: insights from the PALM registry. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2019;8(7):e011765.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.118.011765</pub-id><pub-id pub-id-type="pmcid">PMC6509731</pub-id><pub-id pub-id-type="pmid">30913959</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Research C, for DE and. FDA Drug Safety Communication.: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. FDA [Internet]. 2019 Jun 18 [cited 2025 Jun 18]; Available from: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor</ext-link></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="other">Arca M, Averna M, Borghi C, Lettino M, Perrone Filardi P, Alberti A et al. [How to overcome barriers to implementation of prevention and management strategies of atherosclerotic cardiovascular disease through lipid-lowering therapy]. G Ital Cardiol. 2006. 2023;24(10):770&#8211;80.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1714/4100.40977</pub-id><pub-id pub-id-type="pmid">37767829</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Barrado</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Gomez-Turegano</surname><given-names>P</given-names></name><name name-style="western"><surname>Ortiz-Cortes</surname><given-names>C</given-names></name><name name-style="western"><surname>Vega-Fernandez</surname><given-names>J</given-names></name><name name-style="western"><surname>Gomez-Turegano</surname><given-names>M</given-names></name><name name-style="western"><surname>De Garciperez</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Low-Density lipoprotein cholesterol targets in patients with coronary heart disease in Extremadura (Spain): LYNX registry</article-title><source>Cardiol Res</source><year>2020</year><volume>11</volume><issue>5</issue><fpage>311</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">32849966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14740/cr1079</pub-id><pub-id pub-id-type="pmcid">PMC7430891</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Gomez-Barrado JJ, Gomez-Turegano P, Ortiz-Cortes C, Vega-Fernandez J, Gomez-Turegano M, De Garciperez FJ, et al. Low-Density lipoprotein cholesterol targets in patients with coronary heart disease in Extremadura (Spain): LYNX registry. Cardiol Res. 2020;11(5):311&#8211;8.<pub-id pub-id-type="pmid">32849966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14740/cr1079</pub-id><pub-id pub-id-type="pmcid">PMC7430891</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaviria-Mendoza</surname><given-names>A</given-names></name><name name-style="western"><surname>Machado-Duque</surname><given-names>ME</given-names></name><name name-style="western"><surname>Machado-Alba</surname><given-names>JE</given-names></name><name name-style="western"><surname>Gaviria-Mendoza</surname><given-names>A</given-names></name><name name-style="western"><surname>Machado-Duque</surname><given-names>ME</given-names></name><name name-style="western"><surname>Machado-Alba</surname><given-names>JE</given-names></name></person-group><article-title>Lipid-lowering drug prescriptions in a group of Colombian patients</article-title><source>Biom&#233;dica</source><year>2019</year><volume>39</volume><issue>4</issue><fpage>759</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">31860186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7705/biomedica.4801</pub-id><pub-id pub-id-type="pmcid">PMC7363356</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Gaviria-Mendoza A, Machado-Duque ME, Machado-Alba JE, Gaviria-Mendoza A, Machado-Duque ME, Machado-Alba JE. Lipid-lowering drug prescriptions in a group of Colombian patients. Biom&#233;dica. 2019;39(4):759&#8211;68.<pub-id pub-id-type="pmid">31860186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7705/biomedica.4801</pub-id><pub-id pub-id-type="pmcid">PMC7363356</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ram&#237;rez-Pe&#241;a</surname><given-names>T</given-names></name><name name-style="western"><surname>Corredor-Orlandelli</surname><given-names>D</given-names></name><name name-style="western"><surname>Fern&#225;ndez-&#193;vila</surname><given-names>DG</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>&#193;A</given-names></name><name name-style="western"><surname>Mu&#241;oz-Velandia</surname><given-names>&#211;</given-names></name></person-group><article-title>Frecuencia y Distribuci&#243;n geogr&#225;fica de La Prescripci&#243;n de inhibidores de PCSK9 En Colombia Entre 2019 y 2021</article-title><source>REC CardioClinics</source><year>2025</year><volume>60</volume><issue>1</issue><fpage>17</fpage><lpage>25</lpage></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Ram&#237;rez-Pe&#241;a T, Corredor-Orlandelli D, Fern&#225;ndez-&#193;vila DG, Garc&#237;a &#193;A, Mu&#241;oz-Velandia &#211;. Frecuencia y Distribuci&#243;n geogr&#225;fica de La Prescripci&#243;n de inhibidores de PCSK9 En Colombia Entre 2019 y 2021. REC CardioClinics. 2025;60(1):17&#8211;25.</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saldarriaga-Giraldo</surname><given-names>CI</given-names></name></person-group><article-title>El futuro de La cardiolog&#237;a En colombia: retos y oportunidades</article-title><source>Rev Colomb Cardiol</source><year>2024</year><volume>31</volume><issue>4</issue><fpage>183</fpage><lpage>5</lpage></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Saldarriaga-Giraldo CI. El futuro de La cardiolog&#237;a En colombia: retos y oportunidades. Rev Colomb Cardiol. 2024;31(4):183&#8211;5.</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Colivicchi F, Fabbri G, Oliva F, Abrignani MG, Arca M, Averna M et al. LDL-cholesterol levels and lipid lowering therapy in secondary prevention. Baseline data from the BRING-UP prospective registry. Int J Cardiol [Internet]. 2025 Aug 15 [cited 2025 Jun 18];433. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.internationaljournalofcardiology.com/article/S0167-5273(25)00333-X/fulltext">https://www.internationaljournalofcardiology.com/article/S0167-5273(25)00333-X/fulltext</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcard.2025.133290</pub-id><pub-id pub-id-type="pmid">40258403</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yepes</surname><given-names>CE</given-names></name><name name-style="western"><surname>Mar&#237;n</surname><given-names>YA</given-names></name></person-group><article-title>The challenges of health situation analysis in Colombia</article-title><source>Biom&#233;dica</source><year>2018</year><volume>38</volume><issue>2</issue><fpage>162</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">30184342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7705/biomedica.v38i0.3594</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Yepes CE, Mar&#237;n YA. The challenges of health situation analysis in Colombia. Biom&#233;dica. 2018;38(2):162&#8211;72.<pub-id pub-id-type="pmid">30184342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7705/biomedica.v38i0.3594</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruano</surname><given-names>AL</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>D</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>PG</given-names></name><name name-style="western"><surname>Maceira</surname><given-names>D</given-names></name></person-group><article-title>Understanding inequities in health and health systems in Latin America and the caribbean: a thematic series</article-title><source>Int J Equity Health</source><year>2021</year><volume>20</volume><issue>1</issue><fpage>94</fpage><pub-id pub-id-type="pmid">33823879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12939-021-01426-1</pub-id><pub-id pub-id-type="pmcid">PMC8023548</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Ruano AL, Rodr&#237;guez D, Rossi PG, Maceira D. Understanding inequities in health and health systems in Latin America and the caribbean: a thematic series. Int J Equity Health. 2021;20(1):94.<pub-id pub-id-type="pmid">33823879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12939-021-01426-1</pub-id><pub-id pub-id-type="pmcid">PMC8023548</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castro-Rodr&#237;guez</surname><given-names>A</given-names></name><name name-style="western"><surname>Machado-Duque</surname><given-names>ME</given-names></name><name name-style="western"><surname>Medina-Morales</surname><given-names>DA</given-names></name><name name-style="western"><surname>Machado-Alba</surname><given-names>JE</given-names></name></person-group><article-title>Identification of potentially inappropriate cardiovascular prescriptions in the elderly using beers&#8217; criteria</article-title><source>Rev Colomb Cardiol</source><year>2020</year><volume>27</volume><issue>2</issue><fpage>90</fpage><lpage>6</lpage></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Castro-Rodr&#237;guez A, Machado-Duque ME, Medina-Morales DA, Machado-Alba JE. Identification of potentially inappropriate cardiovascular prescriptions in the elderly using beers&#8217; criteria. Rev Colomb Cardiol. 2020;27(2):90&#8211;6.</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murillo-Mu&#241;oz</surname><given-names>MM</given-names></name><name name-style="western"><surname>Gaviria-Mendoza</surname><given-names>A</given-names></name><name name-style="western"><surname>Machado-Alba</surname><given-names>JE</given-names></name></person-group><article-title>Potential prescribing omissions in patients with cardiovascular disease</article-title><source>Int J Clin Pract</source><year>2019</year><volume>73</volume><issue>12</issue><fpage>e13428</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijcp.13428</pub-id><pub-id pub-id-type="pmid">31573715</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Murillo-Mu&#241;oz MM, Gaviria-Mendoza A, Machado-Alba JE. Potential prescribing omissions in patients with cardiovascular disease. Int J Clin Pract. 2019;73(12):e13428.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ijcp.13428</pub-id><pub-id pub-id-type="pmid">31573715</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavina</surname><given-names>C</given-names></name><name name-style="western"><surname>Seabra-Carvalho</surname><given-names>D</given-names></name><name name-style="western"><surname>Aguiar</surname><given-names>C</given-names></name><name name-style="western"><surname>Anastassopoulou</surname><given-names>A</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>C</given-names></name><name name-style="western"><surname>Ruivo</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Characterization and LDL&#8208;C management in a cohort of high and very high cardiovascular risk patients: the PORTRAIT&#8208;DYS study</article-title><source>Clin Cardiol</source><year>2023</year><volume>47</volume><issue>1</issue><fpage>e24183</fpage><pub-id pub-id-type="pmid">37933175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/clc.24183</pub-id><pub-id pub-id-type="pmcid">PMC10766132</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Gavina C, Seabra-Carvalho D, Aguiar C, Anastassopoulou A, Teixeira C, Ruivo JA, et al. Characterization and LDL&#8208;C management in a cohort of high and very high cardiovascular risk patients: the PORTRAIT&#8208;DYS study. Clin Cardiol. 2023;47(1):e24183.<pub-id pub-id-type="pmid">37933175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/clc.24183</pub-id><pub-id pub-id-type="pmcid">PMC10766132</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>R&#243;denas</surname><given-names>E</given-names></name><name name-style="western"><surname>Escalona</surname><given-names>R</given-names></name><name name-style="western"><surname>Pariggiano</surname><given-names>I</given-names></name><name name-style="western"><surname>Oristrell</surname><given-names>G</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>B</given-names></name><name name-style="western"><surname>Belahnech</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Individual trends in LDL-C control in patients with previous myocardial infarction</article-title><source>REC CardioClinics</source><year>2020</year><volume>55</volume><issue>1</issue><fpage>23</fpage><lpage>9</lpage></element-citation><mixed-citation id="mc-CR54" publication-type="journal">R&#243;denas E, Escalona R, Pariggiano I, Oristrell G, Miranda B, Belahnech Y, et al. Individual trends in LDL-C control in patients with previous myocardial infarction. REC CardioClinics. 2020;55(1):23&#8211;9.</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McEvoy</surname><given-names>JW</given-names></name><name name-style="western"><surname>Jennings</surname><given-names>C</given-names></name><name name-style="western"><surname>Kotseva</surname><given-names>K</given-names></name><name name-style="western"><surname>De Bacquer</surname><given-names>D</given-names></name><name name-style="western"><surname>De Backer</surname><given-names>G</given-names></name><name name-style="western"><surname>Erlund</surname><given-names>I</given-names></name><etal/></person-group><article-title>Variation in secondary prevention of coronary heart disease: the INTERASPIRE study</article-title><source>Eur Heart J</source><year>2024</year><volume>45</volume><issue>39</issue><fpage>4184</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">39212219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehae558</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">McEvoy JW, Jennings C, Kotseva K, De Bacquer D, De Backer G, Erlund I, et al. Variation in secondary prevention of coronary heart disease: the INTERASPIRE study. Eur Heart J. 2024;45(39):4184&#8211;96.<pub-id pub-id-type="pmid">39212219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehae558</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkinson</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Xu</surname><given-names>I</given-names></name><name name-style="western"><surname>Vasudevan</surname><given-names>RS</given-names></name><name name-style="western"><surname>You</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name><name name-style="western"><surname>Taub</surname><given-names>PR</given-names></name></person-group><article-title>Trends in LDL-C following coronary angiography involving assessment by fractional flow reserve in obstructive vs non-obstructive coronary artery disease</article-title><source>Am J Prev Cardiol</source><year>2023</year><volume>13</volume><fpage>100473</fpage><pub-id pub-id-type="pmid">36865903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajpc.2023.100473</pub-id><pub-id pub-id-type="pmcid">PMC9971059</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Wilkinson MJ, Xu I, Vasudevan RS, You H, Xu R, Taub PR. Trends in LDL-C following coronary angiography involving assessment by fractional flow reserve in obstructive vs non-obstructive coronary artery disease. Am J Prev Cardiol. 2023;13:100473.<pub-id pub-id-type="pmid">36865903</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajpc.2023.100473</pub-id><pub-id pub-id-type="pmcid">PMC9971059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldeyer</surname><given-names>C</given-names></name><name name-style="western"><surname>Seiffert</surname><given-names>M</given-names></name><name name-style="western"><surname>Staebe</surname><given-names>N</given-names></name><name name-style="western"><surname>Braetz</surname><given-names>J</given-names></name><name name-style="western"><surname>Kohsiack</surname><given-names>R</given-names></name><name name-style="western"><surname>Ojeda</surname><given-names>F</given-names></name><etal/></person-group><article-title>Lipid management after first diagnosis of coronary artery disease: contemporary results from an observational cohort study</article-title><source>Clin Ther</source><year>2017</year><volume>39</volume><issue>11</issue><fpage>2311</fpage><lpage>e23202</lpage><pub-id pub-id-type="pmid">29103665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2017.10.005</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Waldeyer C, Seiffert M, Staebe N, Braetz J, Kohsiack R, Ojeda F, et al. Lipid management after first diagnosis of coronary artery disease: contemporary results from an observational cohort study. Clin Ther. 2017;39(11):2311&#8211;e23202.<pub-id pub-id-type="pmid">29103665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2017.10.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dansinger</surname><given-names>ML</given-names></name><name name-style="western"><surname>Williams</surname><given-names>PT</given-names></name><name name-style="western"><surname>Superko</surname><given-names>HR</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>EJ</given-names></name></person-group><article-title>The importance of cholesterol follow-up testing under current Statin treatment guidelines</article-title><source>Prev Med</source><year>2019</year><volume>121</volume><fpage>150</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">30742874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ypmed.2019.02.003</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Dansinger ML, Williams PT, Superko HR, Schaefer EJ. The importance of cholesterol follow-up testing under current Statin treatment guidelines. Prev Med. 2019;121:150&#8211;7.<pub-id pub-id-type="pmid">30742874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ypmed.2019.02.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajtar-Salwa</surname><given-names>R</given-names></name><name name-style="western"><surname>Bobrowska</surname><given-names>B</given-names></name><name name-style="western"><surname>Batko</surname><given-names>J</given-names></name><name name-style="western"><surname>Bartu&#347;</surname><given-names>S</given-names></name><name name-style="western"><surname>Petkow-Dimitrow</surname><given-names>P</given-names></name><name name-style="western"><surname>Krawczyk-O&#380;&#243;g</surname><given-names>A</given-names></name></person-group><article-title>Lipid-Lowering therapy after acute coronary syndrome in outpatient Practice&#8212;How to achieve goal</article-title><source>J Clin Med</source><year>2023</year><volume>12</volume><issue>20</issue><fpage>6579</fpage><pub-id pub-id-type="pmid">37892717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12206579</pub-id><pub-id pub-id-type="pmcid">PMC10607515</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Rajtar-Salwa R, Bobrowska B, Batko J, Bartu&#347; S, Petkow-Dimitrow P, Krawczyk-O&#380;&#243;g A. Lipid-Lowering therapy after acute coronary syndrome in outpatient Practice&#8212;How to achieve goal. J Clin Med. 2023;12(20):6579.<pub-id pub-id-type="pmid">37892717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm12206579</pub-id><pub-id pub-id-type="pmcid">PMC10607515</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><collab>Frequency of Testing for Dyslipidemia</collab></person-group><article-title>A systematic review and budget impact analysis</article-title><source>Ont Health Technol Assess Ser</source><year>2014</year><volume>14</volume><issue>7</issue><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="pmcid">PMC4549576</pub-id><pub-id pub-id-type="pmid">26316921</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Frequency of Testing for Dyslipidemia. A systematic review and budget impact analysis. Ont Health Technol Assess Ser. 2014;14(7):1&#8211;27.<pub-id pub-id-type="pmcid">PMC4549576</pub-id><pub-id pub-id-type="pmid">26316921</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#350;im&#351;ek</surname><given-names>B</given-names></name><name name-style="western"><surname>&#304;nan</surname><given-names>D</given-names></name><name name-style="western"><surname>&#199;&#305;nar</surname><given-names>T</given-names></name><name name-style="western"><surname>Cagdas-Yumurta&#351;</surname><given-names>A</given-names></name><name name-style="western"><surname>Ozan-Tan&#305;k</surname><given-names>V</given-names></name><name name-style="western"><surname>Zeren</surname><given-names>G</given-names></name><etal/></person-group><article-title>Evaluation of Low-density lipoprotein cholesterol target attainment rates according to the 2016 and 2019 European society of cardiology/ European atherosclerosis society dyslipidemia guidelines for secondary prevention in patients with acute myocardial infarction</article-title><source>Rev Investig Cl&#237;nica</source><year>2021</year><volume>73</volume><issue>6</issue><fpage>371</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.24875/RIC.21000152</pub-id><pub-id pub-id-type="pmid">34098569</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">&#350;im&#351;ek B, &#304;nan D, &#199;&#305;nar T, Cagdas-Yumurta&#351; A, Ozan-Tan&#305;k V, Zeren G, et al. Evaluation of Low-density lipoprotein cholesterol target attainment rates according to the 2016 and 2019 European society of cardiology/ European atherosclerosis society dyslipidemia guidelines for secondary prevention in patients with acute myocardial infarction. Rev Investig Cl&#237;nica. 2021;73(6):371&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.24875/RIC.21000152</pub-id><pub-id pub-id-type="pmid">34098569</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kini</surname><given-names>V</given-names></name><name name-style="western"><surname>Ho</surname><given-names>PM</given-names></name></person-group><article-title>Interventions to improve medication adherence: A review</article-title><source>JAMA</source><year>2018</year><volume>320</volume><issue>23</issue><fpage>2461</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">30561486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.19271</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Kini V, Ho PM. Interventions to improve medication adherence: A review. JAMA. 2018;320(23):2461&#8211;73.<pub-id pub-id-type="pmid">30561486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.19271</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>P</given-names></name><name name-style="western"><surname>Avezum</surname><given-names>&#193;</given-names></name><name name-style="western"><surname>Ramasundarahettige</surname><given-names>C</given-names></name><name name-style="western"><surname>Mony</surname><given-names>PK</given-names></name><name name-style="western"><surname>Yusuf</surname><given-names>R</given-names></name><name name-style="western"><surname>Kazmi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Secondary prevention medications in 17 countries grouped by income level (PURE)</article-title><source>JACC</source><year>2025</year><volume>85</volume><issue>5</issue><fpage>436</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">39909677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2024.10.121</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Joseph P, Avezum &#193;, Ramasundarahettige C, Mony PK, Yusuf R, Kazmi K, et al. Secondary prevention medications in 17 countries grouped by income level (PURE). JACC. 2025;85(5):436&#8211;47.<pub-id pub-id-type="pmid">39909677</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2024.10.121</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotseva</surname><given-names>K</given-names></name><name name-style="western"><surname>De Backer</surname><given-names>G</given-names></name><name name-style="western"><surname>De Bacquer</surname><given-names>D</given-names></name><name name-style="western"><surname>Ryd&#233;n</surname><given-names>L</given-names></name><name name-style="western"><surname>Hoes</surname><given-names>A</given-names></name><name name-style="western"><surname>Grobbee</surname><given-names>D</given-names></name><etal/></person-group><article-title>Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European society of cardiology ESC-EORP EUROASPIRE V registry</article-title><source>Eur J Prev Cardiol</source><year>2019</year><volume>26</volume><issue>8</issue><fpage>824</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">30739508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2047487318825350</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Kotseva K, De Backer G, De Bacquer D, Ryd&#233;n L, Hoes A, Grobbee D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European society of cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824&#8211;35.<pub-id pub-id-type="pmid">30739508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2047487318825350</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">Chow CK, Nguyen TN, Marschner S, Diaz R, Rahman O, Avezum A et al. Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Glob Health [Internet]. 2020 Nov 3 [cited 2025 Mar 28];5(11). Available from: <ext-link ext-link-type="uri" xlink:href="https://gh.bmj.com/content/5/11/e002640">https://gh.bmj.com/content/5/11/e002640</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjgh-2020-002640</pub-id><pub-id pub-id-type="pmcid">PMC7640501</pub-id><pub-id pub-id-type="pmid">33148540</pub-id></mixed-citation></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khatib</surname><given-names>R</given-names></name><name name-style="western"><surname>McKee</surname><given-names>M</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>H</given-names></name><name name-style="western"><surname>Chow</surname><given-names>C</given-names></name><name name-style="western"><surname>Rangarajan</surname><given-names>S</given-names></name><name name-style="western"><surname>Teo</surname><given-names>K</given-names></name><etal/></person-group><article-title>Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data</article-title><source>Lancet</source><year>2016</year><volume>387</volume><issue>10013</issue><fpage>61</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">26498706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)00469-9</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2016;387(10013):61&#8211;9.<pub-id pub-id-type="pmid">26498706</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)00469-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moynihan</surname><given-names>R</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>S</given-names></name><name name-style="western"><surname>Michaleff</surname><given-names>ZA</given-names></name><name name-style="western"><surname>Scott</surname><given-names>AM</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J</given-names></name><name name-style="western"><surname>To</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review</article-title><source>BMJ Open</source><year>2021</year><volume>11</volume><issue>3</issue><fpage>e045343</fpage><pub-id pub-id-type="pmid">33727273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2020-045343</pub-id><pub-id pub-id-type="pmcid">PMC7969768</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Moynihan R, Sanders S, Michaleff ZA, Scott AM, Clark J, To EJ, et al. Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review. BMJ Open. 2021;11(3):e045343.<pub-id pub-id-type="pmid">33727273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2020-045343</pub-id><pub-id pub-id-type="pmcid">PMC7969768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>H</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>VD</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M</given-names></name><name name-style="western"><surname>Tariq</surname><given-names>M</given-names></name><name name-style="western"><surname>Mohammad</surname><given-names>RA</given-names></name></person-group><article-title>The impact of the COVID-19 pandemic on medical conditions and medication adherence in people with chronic diseases</article-title><source>J Am Pharm Assoc</source><year>2022</year><volume>62</volume><issue>3</issue><fpage>834</fpage><lpage>e8391</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.japh.2021.11.013</pub-id><pub-id pub-id-type="pmcid">PMC8591859</pub-id><pub-id pub-id-type="pmid">34844885</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Ismail H, Marshall VD, Patel M, Tariq M, Mohammad RA. The impact of the COVID-19 pandemic on medical conditions and medication adherence in people with chronic diseases. J Am Pharm Assoc. 2022;62(3):834&#8211;e8391.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.japh.2021.11.013</pub-id><pub-id pub-id-type="pmcid">PMC8591859</pub-id><pub-id pub-id-type="pmid">34844885</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allahyari</surname><given-names>A</given-names></name><name name-style="western"><surname>Jernberg</surname><given-names>T</given-names></name><name name-style="western"><surname>Hagstr&#246;m</surname><given-names>E</given-names></name><name name-style="western"><surname>Leosdottir</surname><given-names>M</given-names></name><name name-style="western"><surname>Lundman</surname><given-names>P</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>P</given-names></name></person-group><article-title>Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study</article-title><source>Eur Heart J</source><year>2020</year><volume>41</volume><issue>40</issue><fpage>3900</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">32072178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehaa034</pub-id><pub-id pub-id-type="pmcid">PMC7654933</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Allahyari A, Jernberg T, Hagstr&#246;m E, Leosdottir M, Lundman P, Ueda P. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study. Eur Heart J. 2020;41(40):3900&#8211;9.<pub-id pub-id-type="pmid">32072178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehaa034</pub-id><pub-id pub-id-type="pmcid">PMC7654933</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dykun</surname><given-names>I</given-names></name><name name-style="western"><surname>Mahabadi</surname><given-names>AA</given-names></name><name name-style="western"><surname>Rassaf</surname><given-names>T</given-names></name></person-group><article-title>A clinical perspective on the 2019 ESC/EAS guidelines for the management of dyslipidaemias: PCSK-9 inhibitors for all?</article-title><source>Eur Heart J</source><year>2020</year><volume>41</volume><issue>24</issue><fpage>2331</fpage><pub-id pub-id-type="pmid">32031601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehaa005</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Dykun I, Mahabadi AA, Rassaf T. A clinical perspective on the 2019 ESC/EAS guidelines for the management of dyslipidaemias: PCSK-9 inhibitors for all? Eur Heart J. 2020;41(24):2331.<pub-id pub-id-type="pmid">32031601</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehaa005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ballantyne</surname><given-names>CM</given-names></name><name name-style="western"><surname>Virani</surname><given-names>SS</given-names></name></person-group><article-title>Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB?</article-title><source>Eur Heart J</source><year>2020</year><volume>41</volume><issue>40</issue><fpage>3910</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">32268351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehaa139</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Ballantyne CM, Virani SS. Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB? Eur Heart J. 2020;41(40):3910&#8211;2.<pub-id pub-id-type="pmid">32268351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehaa139</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><collab>World Medical Association</collab></person-group><article-title>World medical association declaration of helsinki: ethical principles for medical research involving human subjects</article-title><source>JAMA</source><year>2013</year><volume>310</volume><issue>20</issue><fpage>2191</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">24141714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2013.281053</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">World Medical Association. World medical association declaration of helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191&#8211;4.<pub-id pub-id-type="pmid">24141714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2013.281053</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>